



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|---|--|
| (51) International Patent Classification ⁶ : C12N 1/00 | | A2 | (11) International Publication Number: WO 98/35014 |
| | | | (43) International Publication Date: 13 August 1998 (13.08.98) |
| (21) International Application Number: PCT/IE98/00010 (22) International Filing Date: 11 February 1998 (11.02.98) | | (81) Designated States: AU, CA, JP, MX, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). | |
| (30) Priority Data: PCT/IE97/00007 11 February 1997 (11.02.97) WO (34) Countries for which the regional or international application was filed: AU et al. | | Published <i>Without international search report and to be republished upon receipt of that report.</i> <i>With an indication in relation to a deposited microorganism furnished under Rule 13bis separately from the description.</i> <i>Date of receipt by the International Bureau:</i> <i>09 March 1998 (09.03.1998)</i> | |
| (71) Applicants (for all designated States except US): FORBAIRT trading as BIORESEARCH IRELAND [IE/IE]; Glasnevin, Dublin 9 (IE). UNIVERSITY COLLEGE CORK [IE/IE]; College Road, Cork (IE). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): COLLINS, John, Kevin [IE/IE]; Spur Hill, Doughcloyne, County Cork (IE). O'SULLIVAN, Gerald, Christopher [IE/IE]; Ballinveltig, Curraheen Road, Bishopstown, Cork (IE). THORNTON, Gerardine, Mary [IE/IE]; Ballymah, Waterfall, County Cork (IE). O'SULLIVAN, Marian, Mary, Geraldine [IE/IE]; 126 Castle Farm, Shankill, County Dublin (IE). | | | |
| (74) Agent: ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE). | | | |
| (54) Title: PROBIOTIC STRAINS FROM <i>LACTOBACILLUS SALIVARIUS</i> AND ANTIMICROBIAL AGENTS OBTAINED THEREFROM | | | |
| (57) Abstract | | | |
| <p>A strain of <i>Lactobacillus salivarius</i> isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad spectrum of activity against bacteria including <i>Listeria</i>, <i>Staphylococcus</i> including methicillin resistant <i>St. aureus</i> (MRSA), and <i>Bacillus</i>, but does not inhibit many closely related <i>lactobacilli</i>. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

DescriptionProbiotic strains from *Lactobacillus salivarius* and antimicrobial agents obtained therefromField of the Invention

5 This invention relates to probiotic bacterial strains capable of producing antimicrobial agents which have various applications in food stuffs and in medicine. More particularly, the invention relates to probiotic strains of *Lactobacillus salivarius* and to a peptide antibacterial agent derived therefrom with bacteriocin-like properties.

Background Art

10 Much research has been carried out in the field of human probiotics in the last decade (see review Huis in't Veld *et al.* (1994) *Tibtech* 12, 6-8). This research has been prompted by the rising interest by the public in their health and well-being. Many probiotic products are now available on the market and some of the beneficial effects derived from these products range from alleviation of lactose intolerance (Gilliland, S.E. (1990) *FEMS Microbiol. Rev.* 87, 175-188) to prevention of diarrhoeal diseases (Marteau, P. *et al.* (1993) *FEMS Microbiol. Rev.* 12, 207-220) and possible prevention of carcinogenesis (Adachi, S. (1992) In "The Lactic Acid Bacteria in Health and Disease". (Wood, Ed.), 233-262, Elsevier, Barking). Controversy exists over many of these beneficial effects as no standardised procedures are available and contradictory results have been published with regard to the possible beneficial effects of cultured products containing 'probiotic' bacteria.

15 Poor choice of strain has been cited as one of the contributing factors to the inconsistency and variability of results (Marteau, P. *et al.* (1993) *supra*) (Kim, H.S. (1988) *Cult. Dairy Prod. J.* 23, 6-9) and Fuller, R. ((1989) *J. Appl. Bact.* 66, 365-378) outlined criteria pertaining to the successful isolation of probiotic strains. The strains

should be indigenous to the intended host species and also have the ability to (i) survive and grow within that host; (ii) exert a beneficial effect at the target site and (iii) be maintainable in the carrier food or system throughout product manufacture and storage.

5 There is a fast growing market for health-promoting products including probiotics. Many such products are now available (Jong, S.C. and Birmingham, J.M., (1993) *ATCC Quart. Newslett.* 13(1), 1-11). One of the more important components of these products is the 10 microorganisms used. The most frequently utilised species include *Bifidobacterium* sp., *Lactobacillus* sp., and *Propionibacterium* sp. (O'Sullivan, M.G., *et al.* (1992) *Trends in Food Sci. and Tech.* 3(12), 309-314). There is a lack of substantiated evidence from controlled 15 trials that the organisms currently used in such products are those which have beneficial effects on the gut flora (Tannock, G.W. (1983) *In Human Intestinal Microflora in Health and Disease* 517-539 D. J. Hentges (ed.), New York, Academic Press). The source of the microorganism is critical to its survival and therefore its function in the human intestinal tract. Lee, Y-K and Salminen, S. ((1995) *Trends Food Sci. Technol.* 6, 241-245) stated that as a general requirement, a 20 probiotic strain should be of human origin as some health-promoting effects may be species dependent. It is well known that the indigenous microflora is one of the major defense mechanisms that protects the human against colonisation by allochthonous invading bacteria (Tancrede, C. (1992) *Eur. J. Clin. Microbiol. Infect. Dis.* 11(11), 25 1012-1015) and it is also the human's best ally when supporting the immune system. Bacterial populations at different levels of the gastrointestinal tract constitute complex ecosystems depending on the physiology of the host and on interactions between bacteria.

30 Ten Brink *et al.* ((1994) *Journal of Applied Bacteriology* 77 140-148) isolated and screened a large number (~1000) of *Lactobacillus* strains for the production of antimicrobial activity. *Lactobacilli* were isolated from various fermented foods and feeds (sauerkraut, cheese, sausage and silage), human dental plaque and faeces derived from different laboratory animals (rat, mouse, guinea pig and quail) and

human volunteers. Only eight positive strains were found and two of these were studied, namely *Lactobacillus salivarius* M7 and *Lactobacillus acidophilus* M46. The former strain produces the broad spectrum bacteriocin salivaricin B which inhibits the growth of *Listeria monocytogenes*, *Bacillus cereus*, *Brochothrix thermosphacta*, *Enterococcus faecalis* and many lactobacilli. *L. acidophilus* M46 produces a bacteriocin acidocin B which combines the inhibition of *Clostridium sporogenes* with a very narrow activity spectrum within the genus *Lactobacillus*. However, these strains are not indigenous to the infected host species, which is one of the criteria which is required for a successful probiotic strain for human use.

Arihara, K. *et al.* ((1996) Letters in Applied Microbiology 22, 420-424) have isolated Salivacin 140 a bacteriocin from *Lactobacillus salivarius* subsp. *salicinius* T140. Strain T140 was isolated from the surface of Japanese pampas grass leaves grown close to an animal barn and thus the strain was likely to have derived from animal faeces.

There is a need for probiotic strains which meet the aforementioned criteria. Bacteriocin production by lactobacilli is thought to play an important role in the competitive exclusion of pathogens and other undesirable microorganisms of the intestinal tract of humans. Bacteriocins are broadly defined as proteinaceous compounds which exhibit a bactericidal effect against a wide range of microorganisms.

Due to their diversity of species and habitats lactobacilli are the most bacteriocinogenic of the lactic acid bacteria. As many as forty bacteriocins produced by lactobacilli have now been isolated (Klaenhammer, T.R. (1993) *FEMS Microbiol. Rev.* 12, 39-86).

Bacteriocins have been isolated from human infant faeces. However, the bacteriocins were found to have narrow host ranges and were active only against other lactobacillus species (Toba, T. *et al.* (1991) *Lett. Appl. Microbiol.* 12, 228-231.).

There is a need for bacteriocins with a broad spectrum of activity.

Disclosure of Invention

5 The invention provides a strain of *Lactobacillus salivarius* isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative microorganisms and which secretes a product having antimicrobial activity into a cell - free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E, 10 the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice.

15 Preferably, the strain of *Lactobacillus* according to the invention exhibits a broad - spectrum of activity against bacteria including *Listeria*, *Staphylococcus* and *Bacillus*, but does not inhibit many closely related *lactobacilli*.

20 Two especially preferred stains are *Lactobacillus salivarius* strain UCC 1 (deposited at The National Collections of Industrial and Marine Bacteria Limited (NCIMB) on November 27, 1996, and accorded the accession number NCIMB 40830) and *Lactobacillus salivarius* strain UCC 118 (deposited at NCIMB on November 27, 1996, and accorded the accession number NCIMB 40829) and mutants or variants thereof.

25 The antimicrobial product secreted by the *Lactobacillus salivarius* strains according to the invention may be the expression product of a plasmid or other extrachromosomal entity associated with said strains.

The invention also provides a health promoting product containing a strain of *Lactobacillus salivarius* as hereinbefore defined as a probiotic.

The strains of *Lactobacillus salivarius* according to the invention were isolated from appendices and sections of the large and small intestine of the human gastrointestinal tract (G.I.T.) obtained during reconstructive surgery.

5 A preferred site for the isolation of the strains according to the invention is the small intestine. Any bacteria which prove difficult to maintain in culture were discarded as they would not be suitable to work with under processing or manufacturing conditions.

10 In this way certain strains of *Lactobacillus salivarius* were identified which have a greater chance of survival in the human G.I.T. when compared to many of the probiotic strains currently being used.

The strains according to the invention when subjected to adhesion assays are found to be highly adherent to both Caco-2 and HT-29 cell-lines.

15 The strains of lactobacilli according to the invention are able to survive at pH as low as 2.0. Prior to colonisation and growth of a probiotic in the gastrointestinal tract it must pass through the harsh acidic environment of the stomach. There are four main factors which determine the survival of bacteria on passage through the stomach to 20 reach the intestine, namely the pH of the gastric juice, the buffering capacity of food, the rate of gastric emptying and the quantity and physiological state of the bacterium itself.

25 Gastric acid has been implicated as a major host defence mechanism involved in maintaining the sparse bacterial population of the upper small bowel and aiding resistance against infection by pathogenic microorganisms (germicidal activity). A key factor influencing survival of bacteria in gastric juice is pH.

30 The mechanism of tolerance of a probiotic strain to low pH is of importance for its ability to survive passage through the stomach. Prolonged incubation of the cells of the *lactobacillus* strains according

to the invention in buffered media prior to challenge at low pH values show that they are sensitive to pH 2.0. This observation indicates that these strains possess an inducible acid tolerance mechanism for resistance as hereinafter exemplified.

5 The lactobacillus strains according to the invention also exhibit high bile resistance. It is considered that resistance to bile acids is an important biological strain characteristic required for survival in the hostile environment of the G.I.T. For microorganisms to have a health-promoting capacity in the human intestine not only must they be able to resist the potentially lethal effects of the bile acids present but 10 they must not impinge on the health of the host by producing toxic compounds such as deoxycholic acid (DCA) and lithocholic acid (LCA) which have been implicated in a number of cytotoxic phenomena.

15 The invention also provides an antimicrobial agent obtained from a strain of *Lactobacillus salivarius* according to the invention as hereinbefore defined which has bacteriocin-like properties.

Preferably, the antimicrobial agent according to the invention has the following properties:

20 (i) An apparent molecular weight between 30 and 100 kDa;

(ii) Heat stability;

(iii) Resistance over a wide pH range;

(iv) Resistance to treatment with detergents;

(v) Resistance to organic solvents;

25 (vi) Sensitivity to proteolytic enzymes including proteinase K, pronase E, trypsin, α - chymotrypsin, ficin and papain; and

(vii) Resistance to lipase, catalase, alkaline phosphatase, phospholipase C and lipoprotein lipase.

Two of the *Lactobacillus salivarius* strains according to the invention, namely *L. salivarius* strains UCC 1 and UCC 118 were 5 screened for antimicrobial activity against a set of four indicator strains, *Listeria innocua*, *Pseudomonas fluorescens*, *Escherichia coli* and *Lactobacillus fermentum* KLD. These strains when tested on buffered medium were found to be inhibitory towards *Listeria innocua* and *L. fermentum* KLD indicator strains. Inhibition studies 10 demonstrated that the two strains inhibited a broad range of Gram positive and Gram negative microorganisms. Both strains secreted antimicrobial activity into the cell-free supernatant and this activity was destroyed by proteinase K and pronase E. Therefore, these compounds were considered to be bacteriocins.

15 The *L. salivarius* strains UCC 1 and UCC 118 produce secretory proteinaceous compounds which have been given the code names ABP1 and ABP118, respectively.

ABP1 and ABP118 exhibit quite a broad-spectrum of activity, 20 against bacteria including *Listeria*, *Staphylococcus* and *Bacillus* but do not inhibit closely related lactobacilli, with the exception of *L. fermentum* KLD, or other LAB such as *Leuconostoc*, *Streptococcus* or *Bifidobacterium*. This is an unusual trait of a bacteriocin 25 (Klaenhammer, T.R. (1993) *supra*), and is likely to be advantageous for the use of these strains as probiotics since they would compete against undesirable microorganisms but not against closely related strains. Another unusual feature of the strains is their antagonistic activity towards *Pseudomonas* sp. This is an unusual trait for Gram positive bacteria.

30 UCC strains 1 and 118 have a much broader spectrum of activity than their respective proteinaceous compounds, ABP1 and ABP118. This would suggest that the viable cells produce a product

which either enhances or acts in synergy with ABP1/ABP118 to inhibit the target cell.

ABP1 and ABP118 are not identical bacteriocins (they possess different spectra of inhibition) but are very similar, as both are not active against LAB and each producer is immune to the activity of the other's bacteriocin. Cross immunity may indicate that these bacteriocins act in the same manner. ABP118 is active against some methicillin resistant *S. aureus* (MRSA), *H. pylori* and *P. fluorescens* strains. No reports exist to date in the literature of inhibition of MRSA by a bacteriocin.

The invention also provides a purified fraction of an antimicrobial agent hereinbefore identified as ABP118 and which has the following properties:

- (i) A molecular weight of 5.0 - 5.3 kDa;
- 15 (ii) A relative amino acid composition which has greater than 45% of hydrophobic amino acids, a high proportion of glycine, alanine and leucine, no tryptophan or tyrosine, one methionine and four proline residues;
- 20 (iii) An amino acid sequence - Lys - Arg - Gly - Pro - Asn - C (SEQ ID NO: 1) at or adjacent to the N-terminus; and
- (iv) Comprises an amino acid sequence Asn Met Lys Arg Gly Pro Asn Cys Val Gly Asn Phe Leu Gly Gly Leu Phe Ala Gly Ala Ala Ala Gly Val Pro Gln Gly Pro Cys (SEQ ID NO: 2).

25 The antimicrobial agent ABP118 has an unusually broad spectrum of activity as hereinafter described and exemplified.

The invention also provides a purified fraction of an antimicrobial agent hereinbefore identified as ABP1 and which has the following properties:

- (i) A molecular weight of 5.3 - 6.1 kDa; and
- 5 (ii) A relative amino acid composition which has greater than 28-30% of hydrophobic amino acids, a high proportion of glycine and alanine, no tryptophan and two proline residues.

As indicated above, *Lactobacillus salivarius* strain UCC 118, isolated from human intestine, produces the antibacterial protein, ABP118, which exhibits a broad range of inhibition towards Gram positive and some Gram negative bacteria. ABP118 has been shown to be heat stable, resistant over a wide pH range and resistant to treatment with a number of detergents and organic solvents. It is sensitive to proteolytic enzymes and insensitive to lipase activity. Ultrafiltration suggests an apparent molecular weight between 30- and 100-kDa for a crude extract of ABP118. Growth studies demonstrate that maximum production of ABP118 occurs in MRS broth pH 5.5. Removal of either Tween 80 (Trade Mark) or peptones from this medium results in 50% loss in ABP118 production. *L. salivarius* UCC 118 produces ABP118 in milk-based media and in the presence of physiological concentrations of human bile (0.3% (v/v)). Co-culturing experiments demonstrate the ability of *L. salivarius* UCC 118 to inhibit growth of *Salmonella* in a broth medium. It is considered that this is due to the production of antimicrobial compounds including ABP118.

The bacteriocin ABP118 can be detected in an active and available form in the presence of milk proteins. Thus, milk can be used as a support medium for bacteriocin production in accordance with the invention. Furthermore, the strains of *Lactobacillus salivarius* according to the invention can be used for fermenting milk products.

The above mentioned properties of ABP118, namely pH, temperature and storage stability mean that this bacteriocin is likely to be of value in the food and pharmaceutical industries.

Thus, the antimicrobial agent according to the invention can be used in foodstuffs. It can also be used as a medicament.

The antimicrobial agent according to the invention is particularly useful against methicillin resistant *S. aureus* (MRSA).

As hereinafter demonstrated in Examples 7 and 8, the above amino acid sequence (SEQ ID NO: 2), which was determined from a purified fraction of the bacteriocin, is a partial peptide. This partial peptide was used to design probes which identified an internal gene sequence and from this sequence an 80bp fragment was isolated and sequenced. This DNA sequence was deduced to give a protein sequence which confirms the identity of SEQ ID NO: 2. Thus, the invention provides a DNA sequence coding for the bacteriocin ABP118, namely the DNA sequence 5'ATGAAACGCGGACCCAACTGTGTAGGTAACTTCTTAGGTGGCTATTGCTGGAGCA GCTGCAGGTGTCCCCCAGGGCCC3' (SEQ ID NO: 6).

Brief description of the Drawings

Fig. 1 is a graphic representation of the survival of washed cells of *Lactobacillus* strains (cfu/ml) in MRS broth, pH 2.0 versus time (min);

Fig. 2 is a graphic representation of the survival of washed cells of *Lactobacillus* strains (cfu/ml) in MRS broth, pH 2.0 versus time (min);

Fig. 3 is a graphic representation of the survival of *Lactobacillus* strain UCC 118 (cfu/ml) versus time (min) in unbuffered media and buffered media;

Fig. 4 is a graphic representation indicating growth of *L. salivarius* UCC 118 (log OD 600) and production of ABP118 (AU/ml) versus time (h);

5 Fig. 5A - Fig. 5D are a graphic representation of the bactericidal effect of ABP118 (5000 AU/ml) on washed (and resuspended in buffer) and unwashed log-, and stationary-phase cells of *Bacillus coagulans* 1761;

10 Fig. 6 is a graphic representation of the growth of *Pseudomonas fluorescens* in TSAYE broth with (♦) and without (□) addition of ABP118 (5000 AU/ml);

15 Fig. 7 is a graphic representation of the growth of methicillin resistant *Staphylococcus aureus* 148 (MRSA) in TSAYE broth with (♦) and without (□) addition of ABP118 (5000 AU/ml);

Fig. 8A is a graphic representation of the inhibitory effect of ABP118 on DNA synthesis by *Bacillus coagulans* 1761; and

20 Fig. 8B is a graphic representation of the inhibitory effect of ABP118 on RNA synthesis by *Bacillus coagulans* 1761.

The invention will be further illustrated by the following Examples.

Modes for Carrying Out the Invention

Example 1

Isolation of probiotic bacteria

Appendices and sections of the large and small intestine of the human G.I.T., obtained during reconstructive surgery, were screened for probiotic bacterial strains as shown in Table 1.

Table 1

Gastrointestinal tract tissue samples screened for the presence of probiotic bacteria

5

| | Sample | Location |
|----|--------|---------------------|
| | A | Ileum |
| | B | Colon |
| | C | Ileal-caecal region |
| 10 | D | Appendix |
| | E | Appendix |
| | F | Ileum |
| | G | Ileal-caecal region |

10

15

All samples were stored immediately after surgery at -80°C in sterile containers.

20

25

30

Frozen tissues were thawed, weighed and placed in cysteinated (0.05%) one quarter strength Ringers' solution. Each sample was gently shaken to remove loosely adhering microorganisms (termed - wash 'W'). Following transfer to a second volume of Ringers' solution, the sample was vortexed for 7 min to remove tightly adhering bacteria (termed -sample 'S'). In order to isolate tissue embedded bacteria, samples A, B and C were also homogenised in a Braun blender (termed -homogenate 'H'). The solutions were serially diluted (dilution 10⁻¹ from a wash sample was labelled W1, dilution 10⁻² was labelled W2 and the same labelling system was used for the 'S' and 'H' samples) and spread-plated (100µl) on to the following agar media: RCM (reinforced clostridial media) and RCM adjusted to pH 5.5 using acetic acid; TPY (trypticase, peptone and yeast extract), Chevalier, P. *et al.* (1990) *J. Appl. Bacteriol* 68, 619-624). MRS (deMann, Rogosa and Sharpe); ROG (acetate medium (SL) of Rogosa); LLA (liver-lactose agar of Lapiere); BHI (brain heart infusion agar); LBS (Lactobacillus selective agar) and TSA YE (tryptone soya agar

supplemented with 0.6% yeast extract). All agar media was supplied by Oxoid Chemicals with the exception of TPY agar. Plates were incubated in anaerobic jars (BBL, Oxoid) using CO₂ generating kits (Anaerocult A, Merck) for 2-5 days at 37°C.

5 Gram positive, catalase negative rod-shaped or bifurcated/ pleomorphic bacteria isolates were streaked for purity on to complex non-selective media (MRS and TPY). Isolates were routinely cultivated in MRS or TPY medium unless otherwise stated at 37°C under anaerobic conditions. Presumptive *Lactobacillus* sp. were 10 stocked in 40% glycerol and stored at -20° and -80°C.

Fermentation end-product analysis

Metabolism of the carbohydrate glucose and the subsequent 15 organic acid end-products were examined using an LKB Bromma, Aminex HPX-87H High Performance Liquid Chromatography (HPLC) column. The column was maintained at 60°C with a flow rate of 0.6 ml/min (constant pressure). The HPLC buffer used was 0.01 N H₂SO₄. Prior to analysis, the column was calibrated using 10 mM citrate, 10 20 mM glucose, 20 mM lactate and 10 mM acetate as standards. Cultures were propagated in modified MRS broth for 1-2 days at 37°C anaerobically. Following centrifugation for 10 min at 14.000 g, the supernatant was diluted 1:5 with HPLC buffer and 200 µl was analysed in the HPLC. All supernatants were analysed in duplicate.

Biochemical and physiological characterisation

25 Biochemical and physiological traits of the bacterial isolates were determined to aid identification. Nitrate reduction, indole formation and expression of β-galactosidase activity were assayed. Growth at both 15°C and 45°C, growth in the presence of increasing concentrations of NaCl up to 5.0% and protease activity on gelatin 30 were determined. Growth characteristics of the strains in litmus milk were also assessed.

Species identification

5 The API 50CHL (BioMerieux SA, France) system was used to tentatively identify the *Lactobacillus* species by their carbohydrate fermentation profiles. Overnight MRS cultures were harvested by centrifugation and resuspended in the suspension medium provided with the kit. API strips were inoculated and analysed (after 24 and 48 h) according to the manufacturers' instructions. Identity of the *Lactobacillus* sp. was confirmed by SDS-Polyacrylamide gel electrophoresis analysis (SDS-PAGE) of total cell protein.

10

Enzyme activity profiles

15 The API ZYM system (BioMerieux, France) was used for semi-quantitative measurement of constitutive enzymes produced by the *Lactobacillus* isolates. Bacterial cells from the late logarithmic growth phase were harvested by centrifugation at 14,000g for 10 min. The pelleted cells were washed and resuspended in 50mM phosphate buffer, pH 6.8 to the same optical density. The strips were inoculated in accordance with the manufacturers' instructions, incubated for 4 h at 37°C and colour development recorded.

Antibiotic sensitivity profiles

20 Antibiotic sensitivity profiles of the isolates were determined using the 'disc susceptibility' assay. Cultures were grown up in the appropriate broth medium for 24-48 h, spread-plated (100µl) onto agar media and discs containing known concentrations of the antibiotics were placed onto the agar. Strains were examined for 25 antibiotic sensitivity after 1-2 days incubation at 37° under anaerobic conditions. Strains were considered sensitive if zones of inhibition of 1mm or greater were seen.

Plasmid profile analysis

30 Plasmid profile analysis of ten *Lactobacillus* sp. was performed using the (Anderson, D.L. and McKay L.L., (1983) *Appl. Env. Microbiol.* 46, 549-552) lysis procedure with the following modifications. Bacterial cells were inoculated (4%) into 100 ml MRS broth supplemented with 40mM DL-threonine and incubated for 4-5 h

(mid-log phase). Cells, harvested by centrifugation, were used immediately for the plasmid DNA preparation. Before the lysis step, lysozyme (10 mg/ml) and mutanolysin (10 µg/ml) were added to the cell suspensions and incubated at 37°C for 1 h and subsequently at 4°C for 30 min. After the addition of 5 M NaCl, the lysates were put on ice for 30 min. The DNA was electrophoresed on 0.7% vertical agarose gels in Tris-acetate buffer for 4-5 h at 100V.

Isolation of *Lactobacillus* sp.

Seven tissue sections taken from the human G.I.T. were screened for the presence of strains belonging to the *Lactobacillus* genus. There was some variation between tissue samples as follows. Samples A (ileum) and E (appendix) had the lowest counts with approximately 10² cells isolated per gram of tissue. In comparison, greater than 10³ cfu/g tissue were recovered from the other samples. Similar numbers of bacteria were isolated during the 'wash' and 'sample' steps with slightly higher counts in the 'sample' solutions of F (ileum) and G (ileal-caecal). Of those screened for tightly-adhering bacteria (homogenised), C (ileal-caecal) was the only tissue section that gave significant counts.

During the screening of some tissue sections, for example C and B, there was not a direct correlation between counts obtained during a dilution series. This would indicate that some growth factors, either blood or tissue derived, were being provided for the growth of the fastidious bacteria in the initial suspension which was subsequently diluted out.

Strain selection and characterisation

Approximately fifteen hundred catalase negative bacterial isolates from different samples were chosen and characterised in terms of their Gram reaction, cell size and morphology, growth at 15° and 45°C and fermentation end-products from glucose. Greater than sixty percent of the isolates tested were Gram positive, homofermentative cocci arranged either in tetrads, chains or bunches. Eighteen percent of the isolates were Gram negative rods and heterofermentative coccobacilli.

5 The remaining isolates (twenty-two percent) were predominantly homofermentative coccobacilli. Thirty eight strains were characterised in more detail- 13 isolates from G; 4 from F; 8 from D; 9 from C; 3 from B and 1 from E. All thirty eight isolates tested negative both for nitrate reduction and production of indole from tryptophan.

Species identification

The API 50CHL allowed rapid identification of the *Lactobacillus* isolates.

10 Seven of the isolates were very typical of the *salivarius* species according to their carbohydrate fermentation profiles. All seven fermented fructose, glucose, mannose, sorbose and raffinose efficiently. None fermented amygdaline. There was some variability: four of the strains fermented ribose, two were negative for lactose utilisation and three isolates partially fermented rhamnose. These, 15 however, are not uncommon traits of the *salivarius* sp. (Bergey's Manual). Three of the isolates possessed similiar fermentation profiles to *Lactobacillus casei* subsp. *casei*. They fermented ribose, galactose, glucose, fructose, arbutine, cellobiose, lactose, saccharose, tagatose and gluconate. However, none fermented gentibiose or turanose and one 20 strain was negative for growth on sorbitol and amygdaline. The three isolates fermented glycerol which is a trait common to twenty percent of *casei* subsp. *casei* strains. Five isolates were tentatively classified in the *plantarum/pentosus* group. They were positive for fermentation of ribose, galactose, glucose, fructose, sorbitol, lactose, cellibiose and 25 esculine. All but two fermented melezitose, four were positive for trehalose, two were positive for tagatose and one for gluconate. All fermented L-arabinose but only one fermented D-arabinose. None were able to grow on raffinose. Analysis of total cell protein of the *Lactobacillus* sp. by SDS-PAGE revealed two main species, *salivarius* 30 and *paracasei*.

A summary of the strain identification is included in Table 2. In Table 2 and in the following Tables 3-6 and the related description the prefix UCC has been omitted for the *Lactobacillus* strains.

Table 2

Identification of selected *Lactobacillus* strains
by two different techniques

5

10

15

20

25

30

| Strain | Sugar fermentation profiles | Total cell protein (SDS-PAGE)* |
|--------|-------------------------------------|---|
| | <i>Lactobacillus</i> sp. | |
| 1 | <i>L. salivarius</i> | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 4333 | <i>L. salivarius</i> | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 43310 | <i>L. salivarius</i> | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 43321 | <i>L. salivarius</i> | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 43324 | <i>L. salivarius</i> | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 43332 | <i>L. casei</i> subsp. <i>casei</i> | <i>L. paracasei</i> subsp. <i>paracasei</i> |
| 43336 | <i>L. casei</i> subsp. <i>casei</i> | ND |
| 43338 | <i>L. plantarum</i> | <i>L. paracasei</i> subsp. <i>paracasei</i> |
| 43348 | <i>L. pentosus</i> | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 43361 | ND | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 43362 | <i>L. plantarum</i> | <i>L. paracasei</i> subsp. <i>paracasei</i> |
| 43364 | <i>L. casei</i> subsp. <i>casei</i> | <i>L. paracasei</i> subsp. <i>paracasei</i> |
| 118 | <i>L. salivarius</i> | <i>L. salivarius</i> subsp. <i>salivarius</i> |
| 4231 | <i>L. salivarius</i> | <i>L. paracasei</i> subsp. <i>paracasei</i> |
| 42319 | <i>L. casei rhamnosus/pentosus</i> | ND |
| 42354 | <i>L. casei rhamnosus/pentosus</i> | ND |
| 42361 | <i>L. pentosus</i> | ND |

ND = Not Determined

* SDS-PAGE of cell wall proteins was courtesy of Bruno Pot
(University of Ghent, Belgium)

Enzyme activity profiles

Enzyme activity profiles for the seventeen *Lactobacillus* sp. tested were carried out and the results were as follows:

5 None of the strains exhibited lipase, trypsin, α -chymotrypsin, β -glucuronidase, α -mannosidase or α -fucosidase activities and only weak β -glucosidase, N-acetyl- β -glucosaminidase activity was observed by three (43332, 43338, 43364) of the strains. All the strains tested were characterised by high acid phosphatase activity (means of 5.0) with phosphohydrolase and alkaline phosphatase activity being lower and more strain variable. Significant β -galactosidase activity was expressed by nine of the seventeen strains but little α -galactosidase activity was evident. Moderate to high levels of leucine, valine and 10 cystine arylamidase activity was observed.

Antibiotic sensitivity profiles

15 Antibiotics of human clinical importance were used to ascertain the sensitivity profiles of selected lactobacilli. The lactobacilli tested were sensitive to ampicillin, amoxycillin, cefotaxime, ceftriaxone, ciprofloxacin, cephadrine, rifampicin and chloramphenicol. They were also resistant to netilmicin, trimethoprim, nalidixic acid, 20 amikacin, vancomycin and gentamicin. Variable sensitivity of the lactobacilli to teicoplanin and ceftizoxime was also observed.

Example 2Source and maintenance of strains

25 The *Lactobacillus* strains used were isolated as described in Example 1.

Human gastric juice

Human gastric juice was obtained from healthy subjects by aspiration through a nasogastric tube (Mercy Hospital, Cork, Ireland). It was immediately centrifuged at 13,000 g for 30 min to remove all 30 solid particles, sterilised through 0.45 μ m and 0.2 μ m filters and divided into 40 ml aliquots which were stored at 4°C and -20°C.

The pH and pepsin activity of the samples were measured prior to experimental use. Pepsin activity was measured using the quantitative haemoglobin assay (Gautam, S. and de La Motte, R.S., (1989) *Proteolytic enzymes, a practical approach. Chapter 3.* R.J. Beynon and J.S. Bond (eds.), IRL Press, Oxford University Press; (Dawson, R.M. (1969) In *Data for Biochemical Research* 138. R.M. Dawson, D.C. Elliot and K. M. Jones (eds.), Clarendon Press, Oxford). Briefly, aliquots of gastric juice (1 ml) were added to 5 ml of substrate (0.7 M urea, 0.4% (w/v) bovine haemoglobin (Sigma Chemical Co.), 0.25 M KCl-HCl buffer, pH 2.0) and incubated at 25°C. Samples were removed at 0, 2, 4, 6, 8, 10, 20 and 30 min intervals. Reactions were terminated by the addition of 5% trichloroacetic acid (TCA) and allowed to stand for 30 min without agitation. Assay mixtures were then filtered (Whatman, No. 113), centrifuged at 14,000 g for 15 min and absorbance at 280 nm was measured. One unit of pepsin enzyme activity was defined as the amount of enzyme required to cause an increase of 0.001 units of A_{280} nm per minute at pH 2.0 measured as TCA-soluble products using haemoglobin as substrate.

Growth of lactobacilli at low pH
To determine whether growth of the *Lactobacillus* strains occurred at low pH values equivalent to those found in the stomach, overnight cultures were inoculated (1%) into fresh MRS broth adjusted to pH 4.0, 3.0, 2.0 and 1.0 using 1N HCl. At regular intervals aliquots (1.5 ml) were removed, optical density at 600 nm (OD_{600}) was measured and colony forming units per ml (cfu/ml) calculated using the plate count method. Growth was monitored over a 24-48 h period.

Survival of strains in a low pH environment
Survival of the strains at low pH *in vitro* was investigated using two assays:

(a) Cells were harvested from fresh overnight cultures, washed twice in phosphate buffer (pH 6.5) and resuspended in MRS broth

adjusted to pH 3.5, 3.0, 2.5 and 2.0 (with 1N HCl) to a final concentration of approximately 10^8 cfu/ml for the lactobacilli. Cells were incubated at 37°C and survival measured at intervals of 5, 30, 60 and 120 min using the plate count method.

5 (b) The *Lactobacillus* strains were propagated in buffered MRS broth (pH 6.0) daily for a 5 day period. The cells were harvested, washed and resuspended in pH adjusted MRS broth and survival measured over a 2 h period using the plate count method.

Survival of microorganisms in human gastric juice

10 To determine the ability of the lactobacilli to survive passage through the stomach, an *ex-vivo* study was performed using human gastric juice. Cells from fresh overnight cultures were harvested, washed twice in buffer (pH 6.5) and resuspended in human gastric juice to a final concentration of 10^6 - 10^8 cfu/ml, depending on the 15 strain. Survival was monitored over a 30-60 min incubation period at 37°C. The experiment was performed using gastric juice at pH ~ 1.2 (unadjusted) and pH 2.0 and 2.5 (adjusted using 1N NaOH).

Growth of *Lactobacillus* sp. at low pH

20 The *Lactobacillus* strains (of human origin) grew normally at pH 6.8 and pH 4.5 reaching stationary phase after 8 h with a doubling time of 80-100 min. At pH 3.5 growth was restricted with doubling times increasing to 6-8 h. No growth was observed at pH 2.5 or lower, therefore, survival of the strains at low pH was examined.

Survival of *Lactobacillus* sp. at low pH

25 HCl-adjusted medium:

30 The *Lactobacillus* strains were generally resistant to pH values 3.5, 3.0 and 2.5. At pH 2.0, strain variation became apparent (see Fig. 1). The *Lactobacillus* strains of human origin survived with little log reduction for 1 h, however, *Lactobacillus* 118 had decreased by 2-4 log after 2 h incubation (see Fig. 2).

Human gastric juice:

To determine the ability of *Lactobacillus* strains to survive conditions encountered in the human stomach, viability of the strains was tested in human gastric juice at pH 1.2 and pH 2.5. Gastric juice 5 adjusted to pH 2.5 was used to determine if factors other than pH are important in the inhibition of these strains by gastric juice. The strains according to the invention were recovered after 30 min incubation in gastric juice, pH 1.2, though at a reduced level. In gastric juice, pH 2.5, viability was approximately 100% in most cases, indicating that pH is 10 the major inhibitory factor of gastric juice.

Inducible acid tolerance in *Lactobacillus* sp.

To determine strain survival at low pH after growth in a buffered carrier medium, the strains were grown continuously for one week at pH 7.0 and then challenged in MRS adjusted to pH 2.0-3.5 15 using 1N HCl. The *Lactobacillus* strains were resistant to pH values 3.5 and 3.0. At lower pH a distinct decrease in cell viability was observed. At pH 2.0 a rapid decline in cell number was recorded for example after 1 h incubation resulting in *Lactobacillus* sp. 118 and 20 eight other strains not being recovered (see Fig. 3). After a further incubation of 1h, five strains were recovered and these at levels of approximately 10^5 cfu/ml.

It was observed in this study that prior growth of the *Lactobacillus* strains in buffered medium rendered them much more sensitive, *in vitro*, to low pH. Viable cells were not recovered after 25 30-60 min incubation at pH 2.0. When compared with survival of cells grown in unbuffered medium, it is clear that these strains possess the ability to adapt to a low pH environment after prior growth in pH environments of 4.0-4.5.

Example 3

Lactobacillus strains used were isolated as described in Example 1.

Growth of cultures in the presence of bovine and porcine bile

5 Fresh cultures were streaked onto MRS/TPY agar plates supplemented with bovine bile (B-8381, Sigma Chemical Co. Ltd., Poole) at concentrations of 0.3, 1.0, 1.5, 5.0 and 7.5% (w/v) and porcine bile (B-8631, Sigma Chemical Co. Ltd., Poole) at concentrations of 0.3, 0.5, 1.0, 1.5, 5.0 and 7.5% (w/v). Plates were 10 incubated at 37°C under anaerobic conditions and growth was recorded after 24-48 h.

Growth of cultures in the presence of human bile

15 Bile samples, isolated from several human gall-bladders, were stored at -80°C before use. For experimental work, bile samples were thawed, pooled and sterilised at 80°C for 10 min. Bile acid composition of human bile was determined using reverse-phase HPLC in combination with a pulsed amperometric detector according to the method of (Dekker, R.R. *et al.*, (1991) *Chromatographia* 31 (11/12), 255-256). Human bile was added to MRS/TPY agar medium at a 20 concentration of 0.3% (v/v). Freshly streaked cultures were examined for growth after 24 and 48 h.

Growth in the presence of individual conjugated and deconjugated bile acids

25 Human gall-bladder bile possesses a bile acid concentration of 50-100 mM and dilution in the small intestine lowers this concentration to 5-10 mM (Hofmann, A.F., *et al.*, (1983) *J. Clin. Invest.* 71, 1003-1022). Furthermore, under physiological conditions, bile acids are found as sodium salts. Therefore, cultures were screened 30 for growth on MRS/TPY agar plates containing the sodium salt of each of the following bile acids (Sigma Chemical Co. Ltd., Poole): (a) *conjugated form*: taurocholic acid (TCA); glycocholic acid (GCA); taurodeoxycholic acid (TDCA); glycodeoxycholic acid (GDCA);

taurochenodeoxycholic acid (TCDCA) and glycochenodeoxycholic acid (GCDCA); (b) *deconjugated form*: lithocholic acid (LCA); chenodeoxycholic acid (CDCA); deoxycholic acid (DCA) and cholic acid (CA). For each bile acid concentrations of 1, 3 and 5 mM were used. Growth was recorded after 24 and 48 h anaerobic incubation.

5

Detection of bile acid deconjugation activity

Both a qualitative (agar plate) and a quantitative (HPLC) assay were used to determine deconjugation activity.

10 *Plate assay*: All the cultures were streaked on MRS/TPY agar plates supplemented with (a) 0.3% (w/v) porcine bile, (b) 3 mM TDCA or (c) 3 mM GDCA. Deconjugation was observed as an opaque precipitate surrounding the colonies (Dashkevicz, M.P., *et al.* (1989) *Appl. Env. Microbiol.* 55(1), 11-16).

15

High Performance Liquid Chromatography:

15 Analysis of *in vitro* deconjugation of human bile was performed using HPLC (Dekker, R.R. *et al.*, (1991) *supra*). Briefly, overnight cultures were inoculated (5%) into MRS/TPY broth supplemented with 0.3% (v/v) human bile and were incubated anaerobically at 37°C. At various time intervals over a 24 h period, samples (1 ml) were removed and centrifuged at 14,000 rpm for 10 min. Undiluted cell-free supernatant (30 µl) was then analysed by HPLC.

20

Isolation of *Lactobacillus* variants with increased bile acid resistance

25 A single *Lactobacillus* colony was inoculated into MRS broth containing 0.3% porcine bile and incubated overnight. The culture was centrifuged at 14,000 rpm for 7 min, washed and resuspended in one quarter strength Ringers' solution. One hundred microlitres of a 10⁻³ dilution was spread-plated onto MRS agar plates consisting of a porcine bile gradient from 0.3 to 0.5%. The plates were incubated for 2 days at 37°C. Isolated colonies were picked from the agar sector containing 30 0.5% porcine bile, restreaked onto MRS supplemented with 0.5% porcine bile and incubated overnight. A number of colonies were then resuspended in one quarter strength Ringers' solution, diluted to 10⁻³

and plated onto gradient plates of increasing concentrations of porcine bile (0.5/1.0%, 1.0/1.5%, 1.5/2.0%, 2.0/2.5% and 2.5/3.0%). Colony morphology, Gram stains, wet mounts and catalase tests were performed on the colonies with increased resistance.

5

Resistance to bile (bovine, porcine and human)

10

All seventeen *Lactobacillus* strains tested were capable of growth (bile acid resistance) on three sources of bile used. It was observed that resistance to bovine bile was much higher than to porcine bile. *Lactobacillus* strains were resistant to concentrations up to and including 5.0% bovine bile and fourteen of the seventeen strains grew at 7.5%.

Porcine bile was more inhibitory to all strains as shown in Table 3.

Table 3

Growth of bacterial isolate in the presence of porcine bile

| STRAIN | % (w/v) PORCINE BILE | | | | | | |
|--------------------------|----------------------|-----|-----|-----|-----|-----|-----|
| | 0.0 | 0.3 | 0.5 | 1.0 | 1.5 | 5.0 | 7.5 |
| <i>Lactobacillus</i> sp. | | | | | | | |
| 1 | + | + | - | - | - | - | - |
| 4333 | + | + | - | - | - | - | - |
| 43310 | + | + | - | - | - | - | - |
| 43321 | + | + | - | - | - | - | - |
| 43324 | + | + | - | - | - | - | - |
| 43332 | + | + | + | + | + | - | - |
| 43336 | + | + | - | - | - | - | - |
| 43338 | + | + | - | - | - | - | - |
| 43348 | + | + | + | - | - | - | - |
| 43361 | + | + | + | + | + | + | - |
| 43362 | + | + | - | - | - | - | - |
| 43364 | + | + | - | - | - | - | - |
| 118 | + | + | + | + | - | - | - |
| 4231 | + | + | - | - | - | - | - |
| 42319 | + | + | + | + | + | + | + |
| 42354 | + | + | + | + | + | + | + |
| 42361 | + | + | + | + | + | + | + |

5 - = no growth

+ = confluent growth

Concentrations of 0.5% and higher inhibited the growth of ten of the seventeen *Lactobacillus* strains, whereas *Lactobacillus* sp. 10 42319, 42354 and 42361 grew to confluence at 7.5%.

Regardless of their bile resistance profiles in the presence of both bovine and porcine bile, the *Lactobacillus* strains grew to confluence at the physiological concentration of 0.3% (v/v) human bile.

Resistance to individual conjugated and deconjugated bile acids

The *Lactobacillus* strains, when analysed specifically for their resistance to individual bile acids, grew well in the presence of taurine conjugated bile acids but growth in the presence of glycine conjugated bile acids was variable. *Lactobacillus* isolates grew to confluence on agar medium containing up to and including 5 mM of taurine conjugates TCA, TDCA and TCDCA. Of the glycine conjugates tested, GCDCA was the most inhibitory, with only four of the *Lactobacillus* sp. being able to grow at concentrations of 3 mM and 5 mM. GDCA was less inhibitory and GCA was the least inhibitory of the three glycine conjugates as shown in Table 4.

Table 4

Growth of bacterial isolates in the presence of
glycine-conjugated bile acids

| STRAIN | BILE ACIDS (mM) | | | | | | | | | | | |
|--------------------------|-----------------|---|---|---|------|---|---|---|-----|---|---|---|
| | GCDCA | | | | GDCA | | | | GCA | | | |
| | 0 | 1 | 3 | 5 | 0 | 1 | 3 | 5 | 0 | 1 | 3 | 5 |
| <i>Lactobacillus</i> sp. | | | | | | | | | | | | |
| 1 | + | + | - | - | + | + | - | - | + | + | + | + |
| 4333 | + | + | - | - | + | + | + | + | + | + | + | + |
| 43310 | + | + | - | - | + | + | - | - | + | + | + | + |
| 43321 | + | + | - | - | + | + | - | - | + | + | + | + |
| 43324 | + | + | - | - | + | + | - | - | + | + | + | + |
| 43332 | + | + | - | - | + | + | - | - | + | + | + | + |
| 43336 | + | + | - | - | + | + | + | - | + | + | + | + |
| 43338 | + | + | - | - | + | + | + | - | + | + | + | + |
| 43348 | + | + | - | - | + | + | - | - | + | + | + | + |
| 43361 | + | + | + | + | + | + | + | + | + | + | + | + |
| 43362 | + | + | - | - | + | + | + | - | + | + | + | + |
| 43364 | + | + | - | - | + | + | + | - | + | + | + | + |
| 118 | + | + | - | - | + | + | + | - | + | + | + | + |
| 4231 | + | + | - | - | + | + | + | - | + | + | + | + |
| 42319 | + | + | + | + | + | + | + | + | + | + | + | + |
| 42354 | + | + | + | + | + | + | + | + | + | + | + | + |
| 42361 | + | + | + | + | + | + | + | + | + | + | + | + |

5 In Table 4:

- = no growth; + = confluent growth

GCDCA = glycochenodeoxycholic acid;

GDCA = glycodeoxycholic acid;

10 GCA = glycocholic acid.

All strains grew on agar medium supplemented with 5 mM GCA, however, growth on GDCA was variable.

Growth in the presence of deconjugated bile acids was also 5 tested. All strains were resistant to concentrations of 5 mM LCA. Fifteen of the seventeen *Lactobacillus* strains tested grew in concentrations of up to and including 5 mM DCA. Two strains, *Lactobacillus* sp. 1 and 43348, were sensitive to low concentrations of 10 DCA (1 mM). Growth in the presence of CA was variable as shown in Table 5.

Table 5
 Growth of bacterial isolates in the presence of
 unconjugated cholic acid (CA)

| STRAIN | CHOLIC ACID (mM) | | | |
|--------------------------|------------------|---|---|---|
| | 0 | 1 | 3 | 5 |
| <i>Lactobacillus</i> sp. | | | | |
| 1 | + | - | - | - |
| 4333 | + | - | - | - |
| 43310 | + | + | - | - |
| 43321 | + | - | - | - |
| 43324 | + | + | - | - |
| 43332 | + | + | - | - |
| 43336 | + | + | - | - |
| 43338 | + | + | + | + |
| 43348 | + | - | - | - |
| 43361 | + | + | + | + |
| 43362 | + | + | + | - |
| 43364 | + | + | + | + |
| 118 | + | + | + | - |
| 4231 | + | + | - | - |
| 42319 | + | + | + | + |
| 42354 | + | + | + | + |
| 42361 | + | + | + | + |

- = no growth; + = confluent growth

5

Only eight *Lactobacillus* strains were capable of growing on a concentration of 3 mM CA. Growth of the seventeen strains was not observed in the presence of 1 mM CDCA.

10

Deconjugation activity of *Lactobacillus* sp.

From the growth studies it was observed that some of the strains possessed bile salt deconjugating activity and further investigation identified three of the seventeen *Lactobacillus* strains (43361, 42319 and 42361) which were capable of deconjugating bile acids. This was demonstrated on agar medium supplemented with 0.3% porcine

15

bile, TDCA (3mM) and GDCA (3 mM). In all cases, deconjugation manifested itself as an opaque zone of precipitated deconjugated bile acid surrounding active colonies (Dashkevich, M.P. and Feighner, S.D., (1989)*Appl. Env Microbiol.* 55(1), 11-16).

5 Bile acid deconjugation activity, observed on agar plates, was confirmed using human bile and HPLC analysis of breakdown products. Only conjugated bile acids were detected in the bile sample.

Induction of bile acid resistance

10 A method was devised for the isolation of *Lactobacillus* strains with increased bile acid resistance. Two *Lactobacillus* strains (4333 and 43310) were chosen which were initially unable to grow in the presence of 0.5% porcine bile but which could grow at a concentration of 0.3% (see Table 3 above). Following continuous sub-culturing in the presence of increasing concentrations of porcine bile (0.3% to 15 3.0%), the resistance of strains 4333 and 43310 increased. Strains regularly sub-cultured on MRS agar maintained their induced bile resistance when restreaked onto MRS agar containing 3.0% porcine bile. Furthermore, induced bile resistant strains were subsequently able to deconjugate porcine bile.

20 With increasing concentrations of porcine bile, changes in colony morphology were observed with both strains tested. The colonies were irregular, flat to umbonate, and appeared grey and opaque in the presence of bile. However, when restreaked onto MRS agar, the colonies regained their original, smooth, creamy, convex, 25 glistening appearance. (When viewed under the microscope both colony variants appeared as short rods, singly or in pairs). After prolonged sub-culturing in the absence of bile both strains still deconjugated and maintained resistance to high levels of porcine bile.

Example 4Growth and maintenance of cultures

5 The microorganisms screened for antimicrobial production were the seventeen strains listed in Table 3 and were isolated from the human intestinal tract as described in Example 1. All strains belonged to the UCC culture collection

10 Cultures were maintained as frozen stocks at -20°C in the appropriate growth medium and 40% glycerol. Lactobacilli were routinely cultured in deMann Rogosa Sharpe (MRS) medium at 37°C under strict anaerobic conditions (BBL Gas Jars using the Merck 15 Anaerocult A Gas Pak system).

15 The indicator microorganisms used in this Example, many of which are wildtype strains isolated in the Mercy Hospital, Cork, Ireland, were propagated in the following medium under the following growth conditions: *Staphylococcus* (37°C, aerobic), *Bacillus* (37°C, aerobic), *Pseudomonas* (30°C, aerobic), *Escherichia coli* (37°C, anaerobic), *Salmonella* (37°C, anaerobic) and *Listeria* (30°C, aerobic) in Tryptone Soya broth/agar supplemented with 0.6% yeast extract (TSAYE, Oxoid), *Campylobacter* (37°C, anaerobic), *Bacteroides* (37°C, anaerobic), *Helicobacter* (37°C, anaerobic), *Proteus* (37°C, anaerobic), *Haemophilus* (37°C, anaerobic) and *Pneumococcus* (37°C, anaerobic) on Blood agar medium, *Candida* (37°C, aerobic) in YPD (Yeast (1%), Peptone (2%) and Dextrose (2%)) medium, *Clostridium* (37°C, anaerobic) in Reinforced Clostridial medium (RCM, Oxoid), *Lactococcus* (30°C, aerobic) in M17 medium (Oxoid), *Streptococcus* (37°C, anaerobic) in Todd Hewitt Medium (Oxoid) and *Enterococcus* (37°C, anaerobic) species in Brain Heart Infusion medium (BHI, Merck). All strains were inoculated into fresh growth medium and grown overnight before being used in experiments. Agar sloppies (overlays) and plates were prepared by adding 0.7% (w/v) and 1.5% (w/v) agar to the broth medium, respectively.

Detection of antimicrobial activity

Antimicrobial activity of the above strains was detected using the deferred method (Tagg J.R., *et al.* (1976) *Bacteriol. Rev* 40, 722-756). Indicators used in the initial screening were *L. innocua*, *L. fermentum* KLD, *P. fluorescens* and *E. coli* V517. Briefly, the lactobacilli (MRS) were incubated for 12-16 h. Ten-fold serial dilutions were spread-plated (100 µl) onto MRS agar medium. After overnight incubation, plates with distinct colonies were overlayed with the indicator bacterium. The indicator lawn was prepared by inoculating a molten overlay with 2% (v/v) of an overnight indicator culture which was poured over the surface of the inoculated MRS plates. The plates were re-incubated overnight under conditions suitable for growth of the indicator bacterium. Indicator cultures with inhibition zones greater than 1 mm in radius were considered sensitive to the test bacterium.

This procedure was repeated with the supplementation of all agar media with 2% β -glycerophosphate buffer (Sigma Chemicals, Poole) and catalase (100 Units/ml; Sigma Chemicals, Poole), to eliminate antagonistic activity due to acid and hydrogen peroxide production, respectively. Inhibition due to bacteriophage activity was excluded by flipping the inoculated MRS agar plates upside down and overlaying with the indicator. Bacteriophage can not diffuse through agar.

Detection of antimicrobial activity in the cell-free supernatant

To determine if antimicrobial activity is secretory in nature, lactobacilli (MRS) were grown in broth for 12-16 h, aliquots of culture (500µl) were filter-sterilised (0.45µm) and the cell-free supernatant was assayed for antimicrobial activity against the same four indicator strains. Activity of the cell-free supernatant was determined by a modification of the critical dilution method generally used for assay of bacteriocins (Mayr-Harting, A., *et al.*, (1972) *Methods in Microbiology Vol. 7A*, 315-422). Two-fold serial dilutions were spotted (5µl) onto freshly seeded lawns of *L. innocua* and *L. fermentum* KLD and the plates incubated appropriately. The titre was defined as the reciprocal of the highest dilution of inhibitor

demonstrating complete inhibition of the indicator lawn and was expressed as activity units (AU) per millilitre (ml).

Ammonium sulphate precipitation of antimicrobial activity

The antimicrobial-producing strains, *L. salivarius* 1 and 118, 5 were incubated in MRS broth (800 ml) under anaerobic conditions at 37°C and cells were harvested at the time of maximum production of antimicrobial activity (usually 6-8 h with a 3% inoculum). The supernatant was treated with 40% ammonium sulphate for 1 h at 4°C with constant agitation, held at 4°C overnight and then centrifuged at 10 13,000 g for 30 min. The pellet and the pellicle (the layer at the top of the supernatant) were combined and dissolved in 20 ml of phosphate buffer, pH 6.5. The solutions were dialyzed against 5 l of phosphate buffer, pH 6.5, for 24 h at 4°C with 2-3 changes of buffer. Solutions were then filter sterilised, assayed for antimicrobial activity and stored at 4°C. Ammonium sulphate precipitation of the cell-free supernatant at 15 70% and 100% was also carried out to increase specific activity.

Inhibitory host spectra

The inhibitory spectra of lactobacilli were determined by the method of Tagg, J.R. *et al.* (1976) as described above. Cell-free supernatant (CFS) and ammonium sulphate precipitated solution (APS) 20 were also assayed for inhibitory activity against a wide range of Gram positive and Gram negative microorganisms. Overlays of each indicator were prepared on agar plates and allowed to dry. Spots (5µl) of CFS and APS were placed on the seeded plates, allowed to dry and 25 plates incubated overnight. The agar well-diffusion method was also employed for the inhibition of *Helicobacter*, *Proteus*, *Bacteroides* and *Campylobacter* sp. Agar plates were either overlayed or swabbed with the indicator organism and allowed to dry. Wells (4mm) were made in the agar plates and CFS (30-40µl) was placed in the wells and 30 allowed to diffuse through the agar for 20-40 min at room temperature prior to incubation for 24-48 h after which inhibitory zones were measured.

Sensitivity of antimicrobials to proteolytic enzymes

Aliquots of CFS containing antimicrobial activity from individual producing strains were assayed for their sensitivity to proteolytic enzymes. Proteinase K (50mg/ml, 50 mM KH₂PO₄, pH 7.5) and pronase E (50 mg/ml, 50 mM KH₂PO₄, pH 7.5) were individually incubated for 1 h at 37°C with CFS at 3:1 ratio. Both enzyme-treated and untreated CFS were spotted (5µl) onto freshly seeded indicator overlays agar and incubated appropriately.

Production of antimicrobial activity in human bile

Cultures 1 and 118 were spotted onto buffered MRS agar plates containing 0.3% human bile and incubated anaerobically at 37°C overnight. They were overlayed with indicator strains and incubated for a further 12-18 h. Zones of inhibition greater than 1 mm were considered positive.

Detection of antimicrobial activity

The seventeen lactobacilli were screened for inhibitory activity using *Ls. innocua*, *L. fermentum* KLD, *P. fluorescens* and *E. coli* as indicator microorganisms. When the test strains were inoculated on unbuffered MRS, inhibition of the four indicators was observed. Zones ranging in size from 1 mm to 5 mm were measured. Inhibition of *Ls. innocua* by the lactobacilli produced the largest zones.

Inhibition was not due to hydrogen peroxide since incorporation of catalase to MRS plates during the screening did not affect antimicrobial activity. Similarly, bacteriophage activity was excluded as described above. When the lactobacilli were inoculated onto buffered MRS, very little inhibition towards the indicators was observed. There were two exceptions, *L. salivarius* 1 and 118 which produced zones of inhibition only marginally smaller than those produced in unbuffered MRS against the indicators.

Characterisation of antimicrobial activity

The antimicrobial activity of *Lactobacillus* sp. 1 and 118 was demonstrated to be secreted into the cell-free supernatant after 8 h of

growth in MRS broth when assayed against *Ls. innocua* and *B. coagulans* 1761. CFS of 118 also exhibited inhibition towards *P. fluorescens* but this indicator was less sensitive than the previous two. Inhibition of *E. coli* by either ABP1 or ABP118 was not observed.

5 Titres of up to 2000 AU/ml and 1000 AU/ml (using *Ls. innocua* and *L. fermentum* KLD, respectively) were measured. The inhibitory activities of *L. salivarius* 1 and 118, ABP1 and ABP118 respectively, were found to be proteinaceous, as no inhibition of sensitive indicators was observed with the protease-treated CFS. This indicates that both

10 strains produce bacteriocins.

Inhibitory host spectra

The lactobacilli were seen to inhibit a wide range of both Gram positive and Gram negative indicator microorganisms in both buffered and unbuffered media. Little inhibitory activity was observed towards lactic acid bacteria, such as *Streptococcus* and other lactobacilli. The inhibitory spectra of *L. salivarius* 1 and 118 were quite broad. Little inhibition of lactic acid bacteria was observed, however, inhibition of *Staphylococcus*, *Bacillus*, *Salmonella*, *E. coli*, *Pseudomonas* and *Listeria* species was clearly visualized. This inhibition was also produced in the presence of physiological concentrations of human bile. CFS and APS of 1 and 118, ABP1 and ABP118 respectively, were also tested for inhibitory activity on a wide range of microorganisms and were very active against a number of Gram positive bacteria with ABP118 also being active against the Gram negative microorganism *Pseudomonas fluorescens*. The CFS were not very inhibitory towards other related lactic acid bacteria such as *Lactobacillus* or the *Leuconostoc*, *Lactococcus*, *Bifidobacterium* or *Pediococcus* species. Activity was seen against *Enterococcus* sp. Most noteworthy is the inhibition of strains of *Helicobacter pylori* and methicillin resistant *S. aureus* by ABP118 and ABP1 as shown in

20 Table 6.

25

30

Table 6

Inhibitory spectra of ABP1 and ABP118, produced by *L. salivarius* 1 and 118, respectively

| Indicator strains | ABP118 | ABP1 |
|---|--------|------|
| <i>Lactobacillus salivarius</i> 1 | - | - |
| <i>L. salivarius</i> 118 | - | - |
| <i>Enterococcus faecalis</i> | + | + |
| <i>E. faecium</i> | + | + |
| <i>Staphylococcus aureus</i> 1505 | + | + |
| <i>St. aureus</i> 1551 | + | + |
| <i>St. aureus</i> 1522 | + | + |
| <i>St. aureus</i> 1963 | + | + |
| <i>St. aureus</i> 2044 | +/- | +/- |
| <i>St. aureus</i> 771 | + | + |
| <i>St. aureus</i> 6511 | - | +/- |
| <i>St. aureus</i> MH | + | - |
| <i>St. aureus</i> 148 (methicillin resistant) | + | - |
| <i>St. carnosus</i> | + | + |
| <i>Bacillus subtilis</i> DW | + | + |
| <i>B. cereus</i> DW | + | + |
| <i>B. cereus</i> NCDO 577 | + | - |
| <i>B. thuringensis</i> 1146 | - | + |
| <i>B. megaterium</i> 1773 | + | + |
| <i>B. coagulans</i> 1761 | + | + |
| <i>Clostridium tyrobutyricum</i> 1756 | +/- | +/- |
| <i>C. tyrobutyricum</i> 885A | +/- | +/- |
| <i>C. tyrobutyricum</i> 1757 | +/- | +/- |
| <i>C. tyrobutyricum</i> 1729 | +/- | +/- |
| <i>C. butyricum</i> 7423 | +/- | +/- |

Table 6 (contd.)

| Indicator strains | ABP118 | ABP1 |
|-----------------------------------|--------|------|
| <i>Pneumococcus</i> sp. 788 | +- | +- |
| <i>Pneumococcus</i> sp. 904 | +- | +- |
| <i>Haemophilus</i> sp. | - | - |
| <i>Pseudomonas fluorescens</i> | + | |
| <i>P. fragi</i> | + | |
| <i>Escherichia coli</i> 1266 | - | |
| <i>E. coli</i> V517 | - | |
| <i>E. coli</i> | - | |
| <i>Enterobacter</i> sp. 736 | - | |
| <i>Salmonella typhimurium</i> LT2 | - | |
| <i>S. typhimurium</i> | - | |
| <i>S. enteriditis</i> | - | |
| <i>Helicobacter pylori</i> Pu25 | - | |
| <i>H. pylori</i> Pu35 | + | |
| <i>H. pylori</i> Pu37 | - | |
| <i>Campylobacter</i> sp. | - | |
| <i>Bacteroides</i> sp. 28644-1 | + | nd |
| <i>Bacteroides</i> sp. 28644-2 | + | nd |
| <i>Proteus</i> sp. 776 | - | |
| <i>Proteus</i> sp. 778 | - | |
| <i>Proteus</i> sp. 889 | - | |
| <i>Listeria monocytogenes</i> | + | + |
| <i>Ls. innocua</i> | + | + |

In Table 6:

5 + = inhibition of indicator strains;
- = no inhibition of indicator strains;
+/- = slight inhibition of indicator strains;
nd = not determined

Example 5Growth and maintenance of cultures

Lactobacillus salivarius 118 was isolated, identified and cultured from the human intestinal tract as described in Example 1.

10 The indicator microorganisms used in this Example were propagated in Tryptone Soya broth supplemented with 0.6% yeast extract (TSAYE, Oxoid) under the following growth conditions, *Bacillus* (37°C, aerobic), *Escherichia coli* (37°C, anaerobic), *Salmonella* (37°C, anaerobic) and *Listeria* (30°C, aerobic). All strains were inoculated into fresh growth medium and grown overnight before being used in experiments. Agar sloppies (overlays) and plates were prepared by adding 0.7% (w/v) and 1.5% (w/v) agar to the broth medium, respectively.

Detection of antimicrobial activity

20 *L. salivarius* 118 was grown for 12-16 h in MRS broth and the culture centrifuged at 14,000 g for 10 min. Cell-free supernatant (CFS) was spotted (5-10 µl) onto freshly seeded lawns of *Listeria innocua* and *Bacillus coagulans* 1761. Zones of inhibition were measured.

25 Activity of the CFS was assayed for by a modification of the critical dilution method generally used for assay of bacteriocins (Mayr-Harting *et al.*, (1972) *supra*). Serial dilutions were spotted (5µl) onto freshly seeded lawns of *Ls. innocua* and *B. coagulans* 1761 and the plates incubated appropriately. The titre was defined as the reciprocal of the highest dilution of inhibitor demonstrating complete

inhibition of the indicator lawn and was expressed as activity units (AU) per millilitre (ml).

Ammonium sulphate precipitation of the cell-free supernatant containing ABP118

5 *L. salivarius* 118 was grown in broth (800 ml) under anaerobic conditions at 37°C and cells were harvested after 6-8 h incubation. The supernatant was concentrated using 40% ammonium sulphate for 1 h at 4°C with constant agitation, held at 4°C overnight and then centrifuged at 13,000 g for 30 min. The pellet and the pellicle (the layer at the top 10 of the supernatant) were collected and dissolved in a small volume of phosphate buffer, pH 6.5. The solutions were dialyzed against 5 l of phosphate buffer, pH 6.5, for 24 h at 4°C with 2-3 changes of buffer. Solutions were then filter sterilised, assayed for antimicrobial activity 15 and stored at 4°C. This was used in the following experiments unless otherwise stated.

Factors influencing growth of *L. salivarius* 118 and production of ABP118

pH:

20 *L. salivarius* 118 was grown up overnight in MRS broth (50 ml) at 37°C and then inoculated (2%) into MRS broth (1.5 l) in a fermentation vessel (Model 502D; L.H. Fermentation, Stoke Poges, Bucks.) which was connected to an automatic pH controller, at 37 °C, with gentle agitation (200 rpm) and continuously flushed with 5% CO₂. The following pH conditions were imposed in four different 25 experiments: (1) pH 5.5; (2) pH 5.0; (3) pH 4.5 and (4) pH 4.0 and pH was maintained using 8% ammonium hydroxide solution during the experiment. At regular intervals pH, OD₆₀₀, bacterial counts (cfu/ml) and antimicrobial activity (AU/ml) were recorded over a 24 h period.

Growth medium:

30 Various laboratory media were tested for their ability to support both the growth of *L. salivarius* 118 and the production of ABP118. These included MRS, Brain Heart Infusion (BHI), GM17 and Tryptone Soya broth supplemented with 0.6% yeast extract (TSBYE).

5 The effects of the elimination of media constituents from MRS broth on growth and antimicrobial production was also evaluated. The ingredients eliminated included, a) Tween 80, b) Peptone, c) Yeast extract, d) Beef extract, e) Tween 80 and beef extract and f) Tween 80, beef extract and peptone.

10 15 Growth and antimicrobial production was also monitored in, 13.5% skim milk; 13.5% skim milk supplemented with 0.6% yeast extract; 13.5% skim milk supplemented with 2% glucose and 13.5% skim milk supplemented with 2% glucose and 0.6% yeast extract, and in MRS broth supplemented with 0.3% human bile (obtained from human gall-bladder and sterilised at 80°C for 10 mins). At regular intervals, pH, OD₆₀₀, bacterial counts and antimicrobial activity were recorded. All growth curves were carried out at 37°C under anaerobic conditions.

15 pH and temperature stability of ABP118

20 ABP118 was tested for its stability in both alkaline and acidic conditions. pH of the active CFS was adjusted from 1 to 10 using 1N NaOH and HCl. Solutions were filter-sterilised and after incubation for 1 h at room temperature, activity was calculated before and after adjustment using *Ls. innocua* as the indicator. The pH-adjusted solutions were then readjusted to pH 7 using 1N NaOH and HCl and again incubated for 1 h at room temperature and assayed for AU/ml. Controls used were MRS broth adjusted to the same pH values.

25 To determine the temperature stability of ABP118, aliquots (10 ml) were incubated at various temperatures for different time periods and activity was calculated before and after incubation, using the indicator *Ls. innocua*.

30 Sensitivity of ABP118 to the actions of enzymes, detergents and organic solvents

To determine the nature and stability of the antimicrobial activity, ABP118 was incubated with the following enzymes (in a 3 to 1 ratio) for 30-60 min and assayed for antimicrobial activity:

proteinase K (50 mg/ml, 50 mM KH₂PO₄, pH 7.5); pronase E (50 mg/ml, 50 mM KH₂PO₄, pH 7.5); trypsin (50 mg/ml, 67 mM Na₂PO₄, pH 7.6); α -chymotrypsin (50 mg/ml, 80 mM Tris, pH 7.8); α -amylase (50 mg/ml, 20 mM Na₂PO₄, pH 6.9); protease-free lipase (50 mg/ml); 5 ficin (10 mM KH₂PO₄, pH 7.0); catalase (50,000 U/ml dH₂O); lysozyme (10 mg/ml, 25 mM Tris-HCl, pH 8.0); alkaline phosphatase (80 mM Tris-HCl, pH 8.0); pepsin (10mM HCl); phospholipase C (10 mM KH₂PO₄, pH 7.0) and papain (10 mM KH₂PO₄, pH 7.0). Aliquots (5 μ l) of each of these solutions were spotted onto plates already seeded 10 with *Ls. innocua* and *B. coagulans* 1761. Controls included buffer and enzyme, and ABP118.

ABP118 was also treated with a number of solvents and detergents for 1-2 h at 37°C. The solvents used were, 5% β -mercaptoethanol; 10% chloroform; 10% acetone; 10% isopropanol; 15 25% ethanol; 50% acetonitrile; 10% butanol and 50% dichloromethane. The detergents used included, Tween 80 (1%), Tween 20 (1%), Triton X-100 (1%), N-laurylsarcosine (1%) and SDS (0.1% and 1%). After incubation the solutions were either dialyzed, vacuum-, or freeze-dried and assayed for activity.

20 Enzymatic activity of ABP118

ABP118 was applied to the ZYM kit (BioMerieux, France) which is used to assay for constitutive enzyme activity (see Example 1 above). To assay for haemolytic and proteolytic activity, ABP118 was spotted (10 μ l) on blood agar and skim milk agar plates, respectively. 25 Reactions were recorded after 24 h and 48 h incubation at 37°C.

Determination of molecular size of ABP118 by ultrafiltration

The size of ABP118 was estimated from the cell-free supernatant (CFS) and ammonium sulphate precipitated solution (APS; see Example 4 above) of a *L. salivarius* 118 culture. Aliquots were 30 ultrafiltered through various membranes (Amicon Inc., MA., USA) including 100-, 30-, 10- and 3 kDa molecular exclusion sizes. Bacteriocin activity was determined in retained and flowthrough fractions.

Isolation of variants deficient in ABP118 production

MRS broth (100 ml) inoculated (2%) with *L. salivarius* 118 was incubated at temperatures above that allowing optimal growth (40°, 42° and 45°C). After 36-48 h growth, broths were serially diluted and spread-plated (100µl) onto MRS agar. Colonies were then replica-plated onto MRS agar and MRS agar supplemented with 2% β-glycerophosphate buffer. Plates were overlayed with sensitive indicator (*B. coagulans* 1761) and non-inhibiting colonies were streaked out for purity and stocked in 40% glycerol at -20°C. Growth rates of strains and carbohydrate fermentation profiles (API 50CHL) were recorded and compared to that of the wildtype *L. salivarius* 118.

Co-culturing studies

Associative growth of *L. salivarius* 118 and *Salmonella* (*S. typhimurium* and *S. enteriditis*) was studied in modified MRS medium (without sodium acetate). Indicator and producer strains were inoculated in 1:1 ratio. As a control, strains were also grown singly in the same medium. Inoculated media were incubated anaerobically at 37°C. Samples were taken at regular intervals to determine cell growth (cfu/ml). *Salmonella*-*Shigella* (Oxoid) and MRS (Oxoid) medium were used for the selective enumeration of *Salmonella* and *Lactobacillus*, respectively. Tryptone soya agar supplemented with 0.6% yeast extract (TSAYE) was used to obtain total plate counts. *Salmonella* were also co-cultured 1:1 with a non-ABP118-producing variant of the wildtype *L. salivarius* 118.

25 Nature of the antimicrobial compound ABP118

The inhibitor, ABP118, is protein in nature as it is neutralised by protease enzymes such as pronase E, trypsin and pepsin as shown in Tables 7 and 8 and is also actively secreted in the supernatant.

Table 7

Sensitivity of ABP118 to proteolytic and non-proteolytic enzymes

| | |
|------------------------|---|
| Pronase E | + |
| Proteinase K | + |
| Trypsin | + |
| α -chymotrypsin | + |
| Ficin | + |
| Papain | + |
| Pepsin | + |
| Lipase (protease-free) | - |
| Catalase | - |
| Alkaline phosphatase | - |
| Phospholipase C | - |
| Lipoprotein lipase | - |

5

+ = ABP118 sensitive to enzyme treatment

- = ABP118 resistant to enzymic treatment

10

Table 8

Effect of protease treatment on ABP118 activity

| Treatment | Activity of ABP118 (AU/ml) |
|--|-------------------------------|
| ABP118 (no treatment) | 2000 |
| ABP118 + proteinase K at 37°C x 30 min | 0 |
| ABP118 at 100°C x 15 min | 2000 |
| ABP118 + [proteinase K at 100°C x 15 min] at 37°C x 30 min | 2000 |
| [ABP118 + proteinase K] at 100°C x 15 min | 2000 |
| ([ABP118 + proteinase K] at 37°C x 30 min) at 100°C x 15 min | 0 |

5

Protease eliminated antimicrobial activity which was irretrievable after inactivation of the protease. ABP118 does not appear to have a lipid component based on the fact that lipase had no effect on activity (see Table 7). The compound was active in pH range 1-10 with no reduction in activity (against *Ls. innocua*) observed. It is a heat stable protein retaining 100% activity for at least 1 h at 100°C and with only a 50% loss following severe heat treatment by autoclaving as shown in Table 9.

Table 9

Temperature stability profile of ABP118

| Treatment | Activity of ABP118 (AU/ml) | % Reduction of ABP118 activity |
|----------------|-------------------------------|-----------------------------------|
| Untreated | 2000 | 0 |
| 121°C x 15 min | 1000 | 50 |
| 100°C x 1h | 2000 | 0 |
| 100°C x 2h | 500 | 75 |
| 63°C x 30 min | 2000 | 0 |
| 60°C x 1h | 2000 | 0 |
| 60°C x 2h | 2000 | 0 |
| 37°C x 1 week | 500 | 75 |
| 30°C x 1 week | 1000 | 50 |
| 15°C x 1 week | 2000 | 0 |
| 4°C x 4 months | 2000 | 0 |

The inhibitor ABP118 was also very stable when stored at 4°C for 4 months with no loss in activity. Treatment of the compound with a number of organic solvents and detergents did not result in decreased activity as shown in Table 10.

Table 10

Stability of ABP118 in organic solvents and detergents

| Treatment | Activity of ABP118 (AU/ml) |
|---------------------------------|-------------------------------|
| Untreated | 2000 |
| Organic solvents | |
| Chloroform (10%) | 2000 |
| Acetone (10%) | 2000 |
| Isopropanol (10%) | 2000 |
| Ethanol (25%) | 2000 |
| Acetonitrile (50%) | 2000 |
| Butanol (10%) | 2000 |
| Dichloromethane (50%) | 2000 |
| β -mercaptoethanol (5%) | 2000 |
| Detergents | |
| Tween 80 (Trade Mark) (1%) | 2000 |
| Tween 20 (Trade Mark) (1%) | 2000 |
| Triton X (Trade Mark) -100 (1%) | 2000 |
| N-laurylsarcosine (1%) | 2000 |
| SDS (0.1%) | 2000 |
| SDS (1.0%) | 1500 |

When ABP118 was spotted on skim milk agar, no proteolysis was observed over a 24 h incubation period at 37°C or at room temperature. Reactions on blood agar (rabbit and horse) were less conclusive. Though small zones of lysis were recorded, small zones of lysis were also observed when concentrated MRS broth was spotted on the blood agar plates. The ZYM kit, which assays for a wide range of enzymatic activity including esterase and lipase activity revealed no obvious enzymatic activity for ABP118. Ultrafiltration of culture supernatant and partially-purified ABP118 showed that the majority

of activity was present in the retentate with the 100-kDa cutoff membrane and all activity was retained on the 30-kDa cutoff membrane.

Kinetics of ABP118 production

5 The production of ABP118 was dependent on the phase of growth. The kinetics of growth and antimicrobial production by *L. salivarius* 118 is illustrated in Fig. 4. Production of ABP118 was maximal during the logarithmic phase with a reduction in ABP118 concentration during the stationary phase. Maximum concentration of 10 ABP118 activity was found when pH was controlled at pH 5.5 with up to 4000 AU/ml being produced after 3-4 h when biomass was quite high. At pH 4.0 growth of the culture was reduced and ABP118 was not detected. These studies indicate that ABP118 is produced only by growing and not by non-growing cells.

15 Of the four laboratory media tested, MRS and BHI were the two most suitable for support of production of large concentrations of ABP118. To determine if a less complex medium would still support 20 production of ABP118, the effect of Tween 80, yeast extract and peptone sources was assayed. Results show that in the absence of any one of these, the concentration of ABP118 reached only 50% that of 25 concentration produced in MRS broth. However, ABP118 activity remained more stable in the medium lacking yeast extract than in any other media tested.

30 The ability of a skim milk-based medium to act as a suitable carrier to support the growth of *L. salivarius* 118 and production of ABP118 was investigated. Growth in skim milk, skim milk plus yeast extract, and skim milk plus glucose was quite poor. The pH did not go lower than 5.7 after 12 h incubation and little if any ABP118 activity was detected. However, when *L. salivarius* 118 was grown in skim milk plus yeast extract plus glucose, pH reached a value of 4.4 and 3.87 after 12 and 24 h incubation, respectively. ABP118 activity was detected after 2 h at low levels and the majority of ABP118 (10,000 AU/ml against *B. coagulans* 1761) was produced by late-log to early-

stationary phase of growth. It was also observed that the milk was beginning to clot after 10 h incubation.

5

The growth rate of *L. salivarius* 118 in 0.3% human bile was equivalent to the growth rate in MRS broth. However, only one third of the concentration of ABP118 was produced.

Example 6

Detection of antimicrobial activity

Spot assay:

10 *L. salivarius* 118 was grown in MRS broth and the culture centrifuged at 14,000 g for 10 min. Cell-free supernatant (CFS) was spotted (5-10 μ l) onto freshly seeded lawns of indicator, incubated and zones of inhibition recorded. Activity of the cell-free supernatant was assayed for by a modification of the critical dilution method generally used for assay of bacteriocins (Mayr-Harting *et al.*, (1972) *supra*).
15 Serial dilutions were spotted (5 μ l) onto freshly seeded lawns of *Ls. innocua*, *B. coagulans* 1761 and *L. fermentum* KLD and the plates incubated appropriately. The titre was defined as the reciprocal of the highest dilution of inhibitor demonstrating complete inhibition of the indicator lawn and was expressed as activity units (AU) per millilitre
20 (ml).

Microtitre plate assay:

25 Bacteriocin activity was measured during the purification procedure by the microtitre plate assay as described by Holo, H., *et al.* (1991) *J. Bacteriol.* 173, 3879-3887. Two-fold serial dilutions of bacteriocin extracts (50 μ l) in TSAYE broth were prepared in microtitre plates (Greiner GmbH, Frickenhausen). One hundred and fifty microlitres of fresh indicator culture ($A_{600} \sim 0.1$) and 50 μ l of TSAYE were added and the plates incubated at 37°C. Growth of the indicator strain was measured spectrophotometrically at 600 nm. One bacteriocin unit was defined as the amount of bacteriocin causing 30 50% growth inhibition (50% of the turbidity of the control culture without bacteriocin) in this assay.

Bacteriocin purification

Ammonium sulphate precipitation:

L. salivarius 118 was grown to the late logarithmic phase in 2 l of MRS broth (Oxoid) and centrifuged at 12,000 rpm for 20 min.

5 Ammonium sulphate (300 g/l) was added to the cell-free supernatant, stirred at 4°C for 1 h, and centrifuged at 8,000 rpm for 30 min. The pellet and pellicle (floating solid material) were combined and dissolved in 100 ml H₂O (Fraction I).

Hydrophobic interaction chromatography:

10 Fraction I was mixed with 10 g of amberlite XAD-16 (Supelco) for 30-45 min applied to a column and washed once with H₂O (100 ml) and then twice with 40% ethanol (100 ml). The bacteriocin was eluted from the column with 100 ml (10 x 10 ml) of 70% isopropanol-10 mM HCl (Fraction II).

15 Cation exchange chromatography:

20 Fraction II was adjusted to pH 2-3 with H₂O + 0.1% trifluoroacetic acid (TFA) and immediately applied to a 2 ml S-Sepharose Fast Flow cation exchange column previously equilibrated with 5 mM sodium phosphate buffer, pH 5.4 (buffer A). After subsequent washing with 40 ml of buffer A, the bacteriocin was eluted with 20 ml of 1 M NaCl in buffer A (Fraction III).

C₂/C₁₈ Reverse-phase FPLC:

25 Fraction III was applied to a C₂/C₁₈ reverse-phase FPLC column (Pep RPC) equilibrated with isopropánol containing 0.1% TFA, solution A. The bacteriocin was eluted with a linear gradient ranging from 30-37% solution A for 40 min, followed by a gradient 37-100% solution A for another 5 min. The flow rate was 0.5 ml/min and 1 ml fractions were collected. Each fraction was tested for activity using the microtitre plate assay. Fractions with high 30 bacteriocin activity were mixed and rechromatographed on the reverse-phase column.

Amino acid composition and sequence analysis

The purified bacteriocin was hydrolyzed and analyzed on an amino acid analyzer as described previously (Fykse, E.M., *et al.*, (1988) *Biochem J.* 256, 973-980). The amino acid sequence was 5 performed by Edman degradation with an Applied Biosystems model 477A automatic sequencer with an on-line 120A phenylthiohydantoin amino acid analyser (Cornwell, G.G., *et al.*, (1988) *Biochem. Biophys. Res. Commun.* 154, 648-653) The C-terminal part of the sequence was obtained after cleavage of the bacteriocin with cyanogen bromide 10 (CnBr) (Sletten, K., *et al.*, (1974) *Eur. J. Biochem.* 41, 117-125).

Mode of action of ABP118

Adsorption assays:

Ability of ABP118 to adsorb to the cell wall of sensitive and 15 resistant strains was investigated. Briefly, three overnight cultures of *Ls. innocua*, *L. salivarius* UCC 118, *L. fermentum* KLD, *E. coli* 1266 and *B. coagulans* 1761 were each subcultured in fresh broth (20 ml) and grown to mid-logarithmic phase. Cells were harvested by 20 centrifugation, washed twice in 50 mM sodium phosphate buffer, pH 6.5, and resuspended in buffers pH 4.0, 6.0 and 8.0 containing 2000 AU/ml of ABP118. The mixtures were incubated at 37°C for 2 h. The cells were then removed by centrifugation and the antimicrobial titre of the supernatant was determined. Controls included incubation of 2000 AU/ml of ABP118 with no cells and cells with no ABP118 added.

Bactericidal versus bacteriostatic action of ABP118:

Duplicates of *Ls. innocua*, *L. fermentum* KLD and *B. coagulans* 25 1761 were grown to log-phase (OD_{600} , 0.2-0.5). To one set of cells 5000 AU/ml of ABP118 was added. The second set of cells were washed twice and resuspended in phosphate buffer, pH 6.5 prior to the 30 addition of 5000 AU/ml of ABP118. Growth (cfu/ml) under the appropriate conditions, was monitored for a further 7-8 h. This experiment was repeated using stationary-phase cells.

Effect of ABP118 on DNA, RNA and protein synthesis of sensitive cells:

The sensitive indicator *B. coagulans* 1761 was inoculated (3% (v/v)) into TSAYE growth medium and grown to early log phase (3-4 h) at 37°C. The culture was divided in two. To one half 5000 AU/ml of antimicrobial compound was added while an equivalent volume of growth medium was added to the other half. Each half was then supplemented with a radiolabelled substrate. The following substrates (New England Nuclear Corps.) were used: [5,6-³H]uridine (39.6 Ci/mmol) at 5 µCi/ml; methyl [³H]thymidine (6.7 Ci/mmol) at 5 µCi/ml and L-[³⁵S]methionine (1175 Ci/mmol) at 5 µCi/ml. At regular intervals, samples were removed from the cultures and growth medium added (pH 5.8). Each sample was then supplemented with 15% trichloroacetic acid (TCA), mixed well and incubated on ice for 18 h. The samples were then filtered through glass fiber filters and washed with 5% TCA and dried. Filters were placed in scintillation vials with Beckman Ecolite scintillant and counted in a Beckman liquid scintillation counter.

Purification of ABP118

ABP118, which is produced in the log-phase of growth (see Example 5), was concentrated 20-fold from culture media by ammonium sulphate precipitation (Fraction I) resulting in a 292-fold increase in specific activity with a recovery of 250% as shown in Tables 11 and 12.

Table 11

Purification of ABP118

| Purification stage | Vol. (ml) | Total * A280 | Total act. (BU) |
|---|--------------|-----------------|--------------------|
| Culture supernatant | 2000 | 54,800 | 5,120,000 |
| Fraction | | | |
| I Ammonium sulphate ppt. | | 470 | 12,800,000 |
| | 100 | | |
| II Hydrophobic (interaction (XAD-16)) | 15 | 51 | 192,000 |
| III Cation exchange | | 5.98 | 6,400 |
| | 20 | | |
| IVC ₂ /C ₁₈ Reverse-phase FPLC | 1.5 | 0.192 | 2,400 |

* Total A280 equals the optical density at 280nm multiplied by the volume in ml.

5

Table 12

Purification of ABP118

| Purification stage | Sp. act.* | Increase in sp. act. (fold) | Yield (%) |
|---|-----------|-----------------------------------|--------------|
| Culture supernatant | 93 | 1 | 100 |
| Fraction | | | |
| I Ammonium sulphate ppt. | 27,234 | 292 | 250 |
| II Hydrophobic (interaction (XAD-16)) | 3,765 | 40 | 3.75 |
| III Cation exchange | 1,070 | 12 | 0.13 |
| IVC ₂ /C ₁₈ Reverse-phase FPLC | 12,500 | 135 | 0.047 |

* Specific activity is bacteriocin units (BU) divided by the optical density at 280 nm.

After passing through the hydrophobic XAD-16 column, there was a dramatic loss in specific activity with a yield of 3.75% (Table 12, Fraction II). The final purification step resulting in pure ABP118 was reverse-phase chromatography. The active peak, collected as one fraction, eluted at a concentration of 100% isopropanol. When this peak was reapplied to the column, the pure active peak eluted at 31.5% isopropanol. The specific activity of pure ABP118 was 135-fold greater than the culture supernatant and final recovery was 0.047% (Table 12, Fraction IV). Passing through a cation exchange column prior to FPLC decreased specific activity (Table 12, Fraction III) but resulted in better purification. The final protein concentration was estimated to be 130 μ g/ml.

Amino acid composition and sequence analysis
The amino acid composition of pure ABP118 was determined as shown in Table 13.

Table 13

Amino acid composition of ABP118

| Amino acid | residues/molecules |
|--------------|--------------------|
| Asp/Asn | 4 |
| Glu/Gln | 2 |
| Ser | 1-2 |
| Gly | 8-10 |
| His | 0-1 |
| Arg | 2 |
| Thr | 2 |
| Ala* | 6 |
| Pro* | 4 |
| Met* | 1 |
| Cys | 1 |
| Ile* | 1 |
| Leu* | 5 |
| Phe* | 2 |
| Lys | 2 |
| Val | 2 |
| Total | 43-47 |

5

* hydrophobic amino acids

No unusual amino acids were detected. A high proportion of glycine, alanine and leucine was found. No tryptophan or tyrosine residues were present. On Edman degradation, the N-terminus was blocked. As one methionine residue was present, cyanogen bromide cleavage was performed and five amino acid residues were determined at or adjacent to the N-terminus, -Lys-Arg-Gly-Pro-Asn- C (SEQ ID NO: 1). Of the 43-47 amino acids, twenty-one were hydrophobic. The ability to undergo cyanogen bromide cleavage is indicative of the presence of the methionine residue upstream of the lysine residue at

presence of the methionine residue upstream of the lysine residue at the N-terminus.

Mode of action of ABP118

ABP118 adsorbs to sensitive cells:

5. Adsorption of ABP118 was tested over the pH range 4.0-8.0. It was observed that ABP118 bound to the sensitive cells tested (see Table 14) but not to the resistant producer strain *L. salivarius* UCC 118.

10 **Table 14**
Adsorption of ABP118 (1600 AU/ml) to sensitive and resistant cells under different pH conditions*

| Strain | ABP118 (AU/ml) unadsorbed | | |
|--|---------------------------|------------|------------|
| | pH 4.0 | pH 6.0 | pH 8.0 |
| <i>Lactobacillus fermentum</i> KLD (S) | 1000 (40%) | 800 (50%) | 800 (50%) |
| <i>L. salivarius</i> UCC 118 (R) | 1600 (0%) | 1600 (0%) | 1600 (0%) |
| <i>Escherichia coli</i> 1266 (R) | 1600 (0%) | 1600 (0%) | 800 (50%) |
| <i>Bacillus coagulans</i> 1761 (S) | 1000 (40%) | 1000 (40%) | 1000 (40%) |
| <i>Listeria innocua</i> (S) | 1000 (40%) | 1000 (40%) | 1000 (40%) |

* Figures represent unadsorbed ABP118, % adsorption in brackets

S = ABP118-sensitive strain; R, ABP118-resistant strain

15 ABP118 binding to *E. coli* 1266 was observed at pH 8.0 but not at the lower pH values tested. After 2 h incubation at 37°C, 40% adsorption of ABP118 to sensitive cells was measured. Total adsorption of 100% was never observed. Less adsorption was found when the experiment was repeated at 4°C. When cells were autoclaved, 40% adsorption was recorded for both sensitive and 20 resistant cells. When cells were treated with protease there was little increase in adsorption to either sensitive or resistant cells.

ABP118 possesses both bactericidal and bacteriostatic activity:

The inhibitor ABP118 is bactericidal in nature. The most impressive example of this was the effect ABP118 had on the growth of *B. coagulans* 1761 during both the log-, and stationary-phase of growth (on both unwashed and washed cells; see Figs. 5A - 5D). The broth cleared during the first couple of hours after addition of ABP118 demonstrating the lytic activity of ABP118. The bactericidal activity towards *Ls. innocua* and *L. fermentum* KLD was more evident in the log- phase of growth than in the stationary-phase. It was noticed that a rapid decline in KLD strain cell viability occurred after incubation of stationary-phase cells for 4 h after the addition of ABP118. The activity of ABP118 (5000 AU/ml) was also tested against a Gram negative *P. fluorescens* strain and a methicillin resistant *S. aureus* strain. After 60-90 min incubation a bacteriostatic effect on the growth of both strains was clearly evident (Figs. 6 and 7). After 1 h incubation at 30/37°C the cells were divided in two, ABP118 added to one portion (arrows), and growth was monitored for a further 8-9 h. The line $\blacklozenge - \blacklozenge$ illustrates the bacteriostatic effect of ABP118.

ABP118 inhibits DNA and RNA synthesis:

Addition of 5000 AU/ml of ABP118 to log-phase cells did not result in incorporation of either thymidine or uridine indicating that there was inhibition of synthesis of the macromolecules DNA and RNA, respectively. When no bacteriocin was added, cells actively incorporated thymidine and uridine. Inhibition of protein synthesis was not demonstrated due to the low incorporation of radiolabelled amino acid in both the test and control (probably as a result of the high concentration of free amino acids normally present in TSAYE medium). The results are shown in Fig. 8A and Fig. 8B.

Example 7

30 Amino acid composition and sequence analysis of ABP1

The procedure followed in Example 6 in obtaining the amino acid composition for ABP118 was repeated so as to determine the

amino acid composition of pure ABP1. The amino acid composition is shown in Table 15.

Table 15

5

Amino acid composition of APB1

| Amino acid | residues/molecules |
|------------|--------------------|
| Asp/Asn | 5 |
| Glu/Gln | 6 |
| Ser | 5-6 |
| Gly | 8-9 |
| His | 1 |
| Arg | 2-3 |
| Thr | 2 |
| Ala* | 4-5 |
| Pro* | 2 |
| Ile* | 1-2 |
| Leu* | 3 |
| Phe* | 1 |
| Lys | 3 |
| Tyr | 1 |
| Val* | 2-3 |
| Total | 46-52 |

* hydrophobic amino acids

10

As for ABP118 no unusual amino acids were detected. A high proportion of glycine and alanine was found and a relatively high proportion of leucine. No tryptophan was found, however tyrosine and valine were found. Of the 46-52 amino acids, 13-16 were hydrophobic.

Example 8Sequence of ABP118

5 Total genomic DNA was isolated from UCC118 grown in MRS supplemented with 40mM DL-threonine by the method of Leenhouts *et al.* 1991 (J. Bacteriol. 173:4794-4798) and purified by CsCl-ethidium bromide buoyant density gradient centrifugation, with the following modifications. After pelleting and washing the cells in STE buffer, pH 8.0 (6.7% Sucrose, 50mM Tris/HCl, 1mM EDTA), the repelleted cells were stored at -20°C o/n. The cells were lysed using 10 8mg/ml lysozyme and 50U/ml mutanolysin on ice for 1 hour and then incubated at 37°C for 45 minutes. Before adding SDS solution, 2mg/ml of proteinase K was added and incubated at 55°C for 1 hour.

15 Total genomic DNA for UCC118 was digested with BamHI restriction endonuclease according to the manufacturer's directions (Boehringer Mannheim). Oligonucleotide primers were synthesised on a Beckma Oligo 1000 M DNA synthesizer. A fragment encompassing the putative structural gene of ABP118 was amplified by the polymerase chain reaction (PCR) using BIOTAQ™ polymerase (Bioline) and was subsequently purified from an agarose gel using the 20 Qiaex II gel extraction kit (Quagen). Cloning was performed in the pGEM-T vector system (Promega) followed by transformation into *E. Coli* JM109 competent cells. Potential pGEM-T recombinants were identified by blue-white screening, using isopropyl-β-D-thiogalactoside and 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal). The presence of inserts was confirmed by PCR using the pGEM-T sequencing primers designed to the known sequences of the T7 and 25 SP6 promoters. These PCR amplified fragments were sequenced by the automated DNA sequencer 373 stretch XL (PE Applied Biosystems) using the Dye terminator cycle sequencing ready reaction 30 kit with Ampli Taq DNA polymerase, FS (Applied Biosystems).

Following cyanogen bromide cleavage and subsequent sequencing, a 30 amino acid sequence from the C-terminal region of

ABP118 was obtained including 1 amino acid which could not be identified as indicated below.

Asn Met Lys Arg Gly Pro Asn ? Val* Gly Asn Phe* Leu Gly*
Gly Leu Phe Ala Gly Ala* Ala* Gly Val Pro Leu* Gly Pro-
5 (Ala-Gly-Ile)-Cys (SEQ ID NO: 3).

* indicates probability of more than one amino acid species at positions 8, 11, 13, 19 20, 21 and 25

? unidentified amino acid

() indicates possibility of wrong sequence

10 This sequence was confirmed by PCR with BamHI restricted total DNA using degenerate primers, the forward primers (5'ATGAAACGNNGNCCNAAC3') (SEQ ID NO: 4) being designed to the first six known N-terminal amino acids whereas the reverse primer (5' GGGCCTRNGGNACNCC3') (SEQ ID NO: 5) was 15 designed to amino acids 21 to 26, wherein R = purine. An 80 bp. fragment was isolated and subsequently sequenced as follows,

5'ATGAAACGCGGACCCAACTGTGTAGGTAACCTCTTAG
GTGGTCTATTGCTGGAGCAGCTGCAGGTGTCCCCAAGGGC
CC3 (SEQ ID NO: 6)

20 This DNA sequence was deducted to give the following protein sequence thus confirming the identity of amino acids at positions 7, 8, 11, 13, 19, 20, 21 and 25 in the original sequence.

25 Asn Met Lys Arg Gly Pro Asn Cys Val Gly Asn Phe Leu Gly
Gly Leu Phe Ala Gly Ala Ala Gly Val Pro Gln Gly Pro Cys (SEQ
ID NO: 2).

The DNA sequence showed no homology to known sequences in the data banks.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: FORBAIRT (trading as BioResearch Ireland)
(B) STREET: Glasnevin
(C) CITY: Dublin 9
(E) COUNTRY: Ireland
(F) POSTAL CODE (ZIP): none
(G) TELEPHONE: +353-1-8370177
(H) TELEFAX: +353-1-8370176

(A) NAME: UNIVERSITY COLEGE CORK
(B) STREET: College Road
(C) CITY: Cork
(E) COUNTRY: Ireland
(F) POSTAL CODE (ZIP): none

(A) NAME: COLLINS, John Kevin
(B) STREET: Spur Hill
(C) CITY: Doughcloyne, County Cork
(E) COUNTRY: Ireland
(F) POSTAL CODE (ZIP): none

(A) NAME: O'SULLIVAN, Gerald Christopher
(B) STREET: Ballinvelting, Curraheen Road, Bishopstown
(C) CITY: Cork
(E) COUNTRY: Ireland
(F) POSTAL CODE (ZIP): none

(A) NAME: THORNTON, Gerardine Mary
(B) STREET: Ballymah
(C) CITY: Waterfall, County Cork
(E) COUNTRY: Ireland
(F) POSTAL CODE (ZIP): none

(A) NAME: O'SULLIVAN, Marian Mary Geraldine
(B) STREET: 126 Castle Farm
(C) CITY: Shankill, County Dublin
(E) COUNTRY: Ireland
(F) POSTAL CODE (ZIP): none

(ii) TITLE OF INVENTION: Probiotic strains from *Lactobacillus salivarius* and antimicrobial agents obtained therefrom

(iii) NUMBER OF SEQUENCES: 6

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Lys Arg Gly Pro Asn
1 5

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Asn Met Lys Arg Gly Pro Asn Cys Val Gly Asn Phe Leu Gly Gly Leu
1 5 10 15
Phe Ala Gly Ala Ala Ala Gly Val Pro Gln Gly Pro Cys
20 25

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Asn Met Lys Arg Gly Pro Asn Xaa Val Gly Asn Phe Leu Gly Gly Leu
1 5 10 15
Phe Ala Gly Ala Ala Ala Gly Val Pro Leu Gly Pro Ala Gly Ile Cys
20 25 30

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

ATGAAACGNG GNCCNAAC

18

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GGGCCTRNNGG NACNCC

16

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 80 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

ATGAAACGCG GACCCAATG TGTAGGTAAC TTCTTAGGTG GTCTATTTGC TGGAGCAGCT
GCAGGTGTCC CCCAGGGCCC

60

80

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

Professor J.K. Collins,
Department of Microbiology,
University College Cork,
Cork,
Ireland.

INTERNATIONAL FORM

**RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page**

| | |
|--|---|
| I. IDENTIFICATION OF THE MICROORGANISM | |
| Identification reference given by the DEPOSITOR: Lactobacillus salivarius subsp salivarius (UCC 118) | Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: NCIMB 40829 |
| III. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION | |
| The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable) | |
| III. RECEIPT AND ACCEPTANCE | |
| This International Depository Authority accepts the microorganism identified under I above, which was received by it on 27 November (date of the original deposit) 1996 | |
| IV. RECEIPT OF REQUEST FOR CONVERSION | |
| The microorganism identified under I above was received by this International Depository Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion) | |
| V. INTERNATIONAL DEPOSITORY AUTHORITY | |
| Name: NCHMB Ltd 23 St Machar Drive, Aberdeen AB2 5DD UK | Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s): John Baxter Date: 2 December 1996 |

¹ Where Rule 6.4(d) applies, such date is the date on which the status of International Depository authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

Professor J.K. Collins,
Department of Microbiology,
University College Cork,
Cork,
Ireland.

INTERNATIONAL FORM

VIABILITY STATEMENT
Issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITORY AUTHORITY
Identified on the following page

NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY STATEMENT
IS ISSUED

| I. DEPOSITOR | II. IDENTIFICATION OF THE MICROORGANISM |
|----------------------------|--|
| Name: Address: AS ABOVE | Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: NCIMB 40829 Date of the deposit or of the transfer: 27 November 1996 |

III. VIABILITY STATEMENT

The viability of the microorganism identified under II above was tested
on 27 November 1996 ². On that date, the said microorganism was

¹ viable

³ no longer viable

- 1 Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
- 2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
- 3 Mark with a cross the applicable box.


IV. CONDITIONS UNDER WHICH THE STABILITY TEST HAS BEEN PERFORMED

V. INTERNATIONAL DEPOSITORY AUTHORITY

Name:

NCHMB Ltd
23 St Machar Drive
Aberdeen Scotland
UK AB2 3AY

Address:

Signature(s) of person(s) having the power
to represent the International Depository
Authority or of authorized official(s):

Date: 2 December 1996

Fill in if the information has been requested and if the results of the test were negative.

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

Professor J.K. Collins,
Department of Microbiology,
University College Cork,
Cork,
Ireland.

INTERNATIONAL FORM

**RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page**

| | |
|--|--|
| I. IDENTIFICATION OF THE MICROORGANISM | |
| Identification reference given by the DEPOSITOR: | Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: |
| Lactobacillus salivarius subsp salivarius (UCC 1) | NCIMB 40830 |
| II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION | |
| The microorganism identified under I above was accompanied by: | |
| <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation <small>(Mark with a cross where applicable)</small> | |
| III. RECEIPT AND ACCEPTANCE | |
| This International Depository Authority accepts the microorganism identified under I above, which was received by it on 27 November 1996 <small>(date of the original deposit)</small> | |
| IV. RECEIPT OF REQUEST FOR CONVERSION | |
| The microorganism identified under I above was received by this International Depository Authority on <small>(date of the original deposit)</small> and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on <small>(date of receipt of request for conversion)</small> | |
| V. INTERNATIONAL DEPOSITORY AUTHORITY | |
| Name: | Signature(s) of person(s) having the power to represent the International Depository Authority or of authorized official(s): |
| NCHMB Ltd 23 St Machar Drive Aberdeen Scotland UK AB2 1RY | Signature: <i>Al Baxter</i> Date: 02 December 1996 |
| Address: | |

¹ Where Rule 6.4(d) applies, such date is the date on which the status of International depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

Professor J.K. Collins,
Department of Microbiology,
University College Cork,
Cork,
Ireland.

INTERNATIONAL FORM

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified on the following page

NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY STATEMENT
IS ISSUED

| | |
|--|--|
| I. DEPOSITOR | II. IDENTIFICATION OF THE MICROORGANISM |
| Name: Address: AS ABOVE | Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: NCIMB 40830 Date of the deposit or of the transfer: 27 November 1996 |
| III. VIABILITY STATEMENT The viability of the microorganism identified under II above was tested on 27 November 1996 <p> 1. On that date, the said microorganism was <input checked="" type="checkbox"/> viable <input type="checkbox"/> no longer viable </p> | |

- 1 Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
- 2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
- 3 Mark with a cross the applicable box.


IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED⁴

V. INTERNATIONAL DEPOSITORY AUTHORITY

Name:

NCHMB Ltd.

Address:

23 St Machar Drive
Aberdeen Scotland
UK AB6 1RYSignature(s) of person(s) having the power
to represent the International Depositary
Authority or of authorized official(s):

Date: 2 December 1996

⁴ Fill in if the information has been requested and if the results of the test were negative.

Claims:

1. A strain of *Lactobacillus salivarius* isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative microorganisms and which secretes a product having antimicrobial activity into a cell - free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E, the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice.
5
2. A strain according to Claim 1, wherein the strain exhibits a broad - spectrum of activity against bacteria including *Listeria*, *Staphylococcus* and *Bacillus*, but which does not inhibit many closely related *lactobacilli*.
10
3. *Lactobacillus salivarius* strain UCC 1 or a mutant or variant thereof.
15
4. *Lactobacillus salivarius* strain UCC 118 or a mutant or variant thereof.
20
5. A health promoting product containing a strain of *Lactobacillus salivarius* according to any one of Claims 1 - 4 as a probiotic.
25
6. An antimicrobial agent obtained from a strain of *Lactobacillus salivarius* according to any one of Claims 1-4, which has bacteriocin - like properties.
7. An antimicrobial agent according to Claim 6, which has the following properties:
 - (i) An apparent molecular weight between 30 and 100 kDa;

- (ii) Heat stability;
- (iii) Resistance over a wide pH range;
- (iv) Resistance to treatment with detergents;
- (v) Resistance to organic solvents;
- 5 (vi) Sensitivity to proteolytic enzymes including proteinase K, pronase E, trypsin, α - chymotrypsin, ficin and papain; and
- (vii) Resistance to lipase, catalase, alkaline phosphatase, phospholipase C and lipoprotein lipase.

10 8. A purified fraction of an antimicrobial agent according to Claim 7, which has the following properties:

- (i) A molecular weight of 5.0 - 5.3 kDa;
- (ii) A relative amino acid composition which has greater than 45% of hydrophobic amino acids, a high proportion of glycine, alanine and leucine, no tryptophan or tyrosine, 15 one methionine and four proline residues;
- (iii) An amino acid sequence SEQ ID NO: 1 at or adjacent to the N-terminus; and
- (iv) Comprises an amino acid sequence SEQ ID NO: 2.

20 9. A purified fraction of an antimicrobial agent according to Claim 7, which has the following properties:

- (i) A molecular weight of 5.3 - 6.1 kDa; and

(ii) A relative amino acid composition which has greater than 28-30% of hydrophobic amino acids, a high proportion of glycine and alanine, no tryptophan and two proline residues.


5 10. An antimicrobial agent according to any one of Claims 6 - 9, for use in foodstuffs.

11. An antimicrobial agent according to any one of Claims 6 - 9, for use as a medicament.


10 12. An antimicrobial agent according to any one of Claims 6 - 8, for use against methicillin resistant *S. aureus* (MRSA).

13. The DNA sequence SEQ ID NO: 6 coding for bacteriocin ABP118.

1/10




2/10




3/10

Fig. 3



4/10

Fig. 4



5/10

Fig. 5A






Fig. 5B




Time (h)

Time (h)

6/10


Fig. 5C

—□— cells + ABP118
—●— cells alone




7/10

Fig. 6



8/10

Fig. 7

Log OD₆₀₀

9/10




Fig. 8A

10/10




Fig. 8B

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|---|
| (51) International Patent Classification ⁶ : C12N 1/20, A23C 9/12, A61K 35/74, C12R 1/22 | | A3 | (11) International Publication Number: WO 98/35014 (43) International Publication Date: 13 August 1998 (13.08.98) |
| (21) International Application Number: PCT/IE98/00010 (22) International Filing Date: 11 February 1998 (11.02.98) | | (81) Designated States: AU, CA, JP, MX, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). | |
| <p>(30) Priority Data: PCT/IE97/00007 11 February 1997 (11.02.97) WO</p> <p>(34) Countries for which the regional or international application was filed: AU et al.</p> <p>(71) Applicants (for all designated States except US): FORBAIRT trading as BIORESEARCH IRELAND [IE/IE]; Glasnevin, Dublin 9 (IE). UNIVERSITY COLLEGE CORK [IE/IE]; College Road, Cork (IE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): COLLINS, John, Kevin [IE/IE]; Spur Hill, Doughcloyne, County Cork (IE). O'SULLIVAN, Gerald, Christopher [IE/IE]; Ballinveltig, Curraheen Road, Bishopstown, Cork (IE). THORNTON, Gerardine, Mary [IE/IE]; Ballymah, Waterfall, County Cork (IE). O'SULLIVAN, Marian, Mary, Geraldine [IE/IE]; 126 Castle Farm, Shankill, County Dublin (IE).</p> <p>(74) Agent: ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE).</p> | | <p>Published With international search report. With an indication in relation to a deposited microorganism furnished under Rule 13^{bis} separately from the description. Date of receipt by the International Bureau: 9 March 1998 (09.03.98)</p> <p>(88) Date of publication of the international search report: 19 November 1998 (19.11.98)</p> | |
| <p>(54) Title: PROBIOTIC STRAINS FROM <i>LACTOBACILLUS SALIVARIUS</i> AND ANTIMICROBIAL AGENTS OBTAINED THEREFROM</p> <p>(57) Abstract</p> <p>A strain of <i>Lactobacillus salivarius</i> isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad spectrum of activity against bacteria including <i>Listeria</i>, <i>Staphylococcus</i> including methicillin resistant <i>St. aureus</i> (MRSA), and <i>Bacillus</i>, but does not inhibit many closely related <i>lactobacilli</i>. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CI | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERNATIONAL SEARCH REPORT

In national Application No
PCT/IE 98/00010

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N1/20 A23C9/12 A61K35/74 C12R1/22

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A23C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| X | <p>ARIHARA, K. ET AL.: "Salivacin 140, a novel bacteriocin from <i>Lactobacillus salivarius</i> subsp. <i>salicinicus</i> T140 active against pathogenic bacteria" LETTERS IN APPLIED MICROBIOLOGY, vol. 22, 1996, pages 420-424, XP002072786 cited in the application see page 421, right-hand column, last paragraph - page 423, left-hand column, paragraph 2; tables 1,2</p> <p>---</p> <p>-/-</p> | 1,2,5-7, 10-12 |

Further documents are listed in the continuation of box C

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "S" document member of the same patent family

Date of the actual completion of the international search

27 July 1998

Date of mailing of the international search report

12/08/1998

Name and mailing address of the ISA

European Patent Office, P B -5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl.
Fax. (+31-70) 340-3016

Authorized officer

Donath, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IE 98/00010

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| X | TEN BRINK, B. ET AL.: "Antimicrobial activity of lactobacilli: preliminary characterization and optimization of production of acidocin B, a novel bacteriocin produced by <i>Lactobacillus acidophilus</i> M46" JOURNAL OF APPLIED BACTERIOLOGY, vol. 77, 1994, pages 140-148, XP002072787 cited in the application see page 143, left-hand column, last paragraph - page 147, right-hand column, paragraph 4; tables 1-4 --- | 1,6,7, 10,11 |
| X | WO 89 05849 A (CHR. HANSEN'S LABORATORIUM A/S) 29 June 1989 see page 5, line 2 - page 7, line 6 see page 7, line 23 - page 8, line 7 see page 9, line 4 - page 12, line 12 see page 13, line 12 - line 21; examples 1,4,5,12 --- | 1,5,6, 10,11 |
| X | EP 0 384 319 A (VISKASE CORPORATION) 29 August 1990 see page 3, line 22 - line 58 see page 4, line 15 - line 57 see page 8, line 24 - line 27 --- | 6,10 |
| A | KLAENHAMMER, T.R.: "Genetics of bacteriocins produced by lactic acid bacteria" FEMS MICROBIOLOGY REVIEWS, vol. 12, no. 1-3, 1993, pages 39-86, XP002072788 cited in the application see page 63, right-hand column - page 74, left-hand column ' <i>Lactobacillus</i> ' --- | 1-13 |
| A | JONG, S.C. AND BIRMINGHAM, J.M.: "Probiotics for human and animals" ATCC QUARTERLY NEWSLETTER, vol. 13, no. 1, 1993, pages 1-11, XP002072789 cited in the application see the whole document --- | 1-13 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

In. National Application No

PCT/IE 98/00010

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|--|--|
| WO 8905849 | A 29-06-1989 | NONE | |
| EP 0384319 | A 29-08-1990 | AU 646797 B AU 4993590 A AU 665646 B AU 5302394 A CA 2009990 A EP 0750853 A JP 2300106 A US 5573797 A US 5573800 A US 5573801 A | 10-03-1994 30-08-1990 11-01-1996 24-03-1994 21-08-1990 02-01-1997 12-12-1990 12-11-1996 12-11-1996 12-11-1996 |

THIS PAGE BLANK (USPTO)